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1 
1  INTRODUCTION 
 
1.1 PROBLEM DEFINITION 
 
Loss of pancreatic β‐cell function and/or mass is the common pathogenic hallmark of both 
type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D). In T1D is the loss of β‐
cell mass associated with immune mediated destruction, whereas is T2D initially triggered 
by insulin resistance and in later stages by programmed cell death or apoptosis of pancreatic 
β‐cells (American Diabetes Association, 2014). In order to restore normoglycaemia in 
patients with diabetes, most therapies are focused on either increased insulin secretion from 
the remaining β-cells in T2D, or exogenous insulin application in T1D (Gao et al.., 2016). 
Identification of key regulatory mechanisms and active signaling pathways involved in β‐
cell failure in diabetes will further complete the current knowledge of disease pathogenesis 
and would be crucial for future strategies aiming to prevent β‐cell destruction in diabetes. 
The Islet research laboratory at the University of Bremen has recently identified Mammalian 
Sterile 20‐like kinase 1 (MST1), a central component of the Hippo signaling pathway, as a 
critical regulator of pancreatic β‐cell death in human islets and diabetic rodent models 
(Ardestani et al., 2014). Triggered by diabetogenic stimuli, MST1 is strongly hyperactivated 
in β‐cells and its overexpression induces β‐cell death and impaired insulin secretion. β‐cell 
specific loss of MST1 improves β‐cell viability and function under diabetic conditions in 
vitro and in diabetic mice in vivo (Ardestani et al. 2014).  Further analysis of the upstream 
regulators, which may play a role in regulation of MST1 has identified PH domain leucine‐
rich repeat protein phosphatases 1 and 2 (PHLPP1/2) as endogenous regulator of MST1 
signaling. PHLPP1/2 are able to dephosphorylate and activate MST1 under diabetogenic 
conditions, resulting in increased apoptosis of β‐cell (Ardestani et al., unpublished data). 
Targeting the PHLPP-MST1 pathway may affect signaling pathways of diabetic stimuli 
through modulation of β‐cell homeostatic pathways that regulate islet β‐cell viability and 
function. 
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1.2 AIM OF WORK AND WORKING HYPOTHESIS 
 
The aim of my project is to identify active signaling pathways that regulate pancreatic β‐cell 
survival and function in diabetes. In particular, I hypothesized that: 
1) Inhibition of Hippo kinase MST1 improves β‐cell survival under diabetic conditions. 
2) Restoration of a key component of Hippo pathway; transcriptional co-activator YAP 
blocks β‐cell apoptosis induced by a diabetogenic milieu. 
3) PHLPP1/2 is upregulated in diabetic islets; their overexpression triggers β‐cell death 
and dysfunction and could regulate the MST1 pathway. 
4) mTORC1 signaling is activated in T2D islets and its inhibition improves β‐cell 
function. mTORC1 signaling is a novel regulator of the PHLPP-MST1 apoptotic 
pathway.   
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2 REVIEW OF PUBLICATIONS 
 
2.1 ANATOMY OF THE PANCREAS 
 
The pancreas is part of the gastrointestinal system and has an essential role in systemic 
metabolic regulations and in secreting enzymes for converting food into molecules, which 
our cells use as a fuel for growth and proliferation. It is located in the upper abdomen behind 
the stomach and surrounded by the small intestine, liver and spleen (Suda et al., 2006). The 
pancreas consists of two structurally and functionally distinct compartments: the exocrine 
and the endocrine (Slack, 1995). The exocrine compartment comprises more than 95% of 
the pancreatic mass and its main function is to secrete digestive enzymes into the duodenum, 
whereas the endocrine compartment consists of islets of Langerhans and is responsible for 
the secretion of metabolic hormones (insulin, somatostatin, glucagon and pancreatic 
polypeptides) into the bloodstream. Pancreatic islets comprise only 1-2 % of the pancreatic 
mass (Suda et al., 2006; Slack, 1995) (Fig. 1). 
 
The exocrine pancreas, so-called the acinar gland, mainly consists of acinar and ductal cells. 
Acinar cells secrete at least 22 different digestive enzymes into the pancreatic ducts, 
including proteases, amylases, lipases and nucleases. The ductal cells secrete non-enzymatic 
components into the pancreatic juice, together with a hydrogencarbonate-rich fluid, to 
regulate duodenal pH. Pancreatic juice is secreted into the duodenum through the major 
duodenal papilla called papilla of Vater (Suda et al., 2006; Slack, 1995). 
 
The endocrine pancreas, so-called the Islets of Langerhans, which is surrounded by the 
exocrine cells, are highly coordinated cells, which regulate metabolic homeostasis in 
response to nutrient fluctuations in the body. Islet’s size very between 50-250 m with 
spherical or ellipsoid shape. Most abundant endocrine cells in the islets are β-cells, which 
produce insulin. Other endocrine cells, such as α-cells secrete glucagon, δ-cells secrete 
somatostatin, ε-cells secrete hunger stimulating hormone ghrelin, and PP cells produce 
pancreatic polypeptide. Insulin and glucagon are the critical hormones for glucose 
homeostasis with opposite regulation on the blood sugar (Slack, 1995; Broglio et al., 2003; 
Sussel and Mastraci, 2013).  
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Figure 1: Microscopic anatomy of the human pancreas. Human pancreas consists of head, body and tail. 
The exocrine compartment comprises more than 95 % of the pancreas mass, whereas pancreatic islets only 1-
2 % with high abundance of β-cells (adapted from Encyclopedia Britannica, 2010). 
Slika 1: Mikroskopska zgradba človeške trebušne slinavke. Človeška trebušna slinavka je sestavljena iz 
glave, trupa in repa. Eksokrini del sestavlja več kot 95 % mase trebušne slinavke, endokrini del pa le okoli 1-
2 %. V endokrinem delu so najbolj zastopane β-celice (prirejeno po Encyclopedia Britannica, 2010). 
2.2 INSULIN AND β-CELL’S SENSING OF HIGH GLUCOSE LEVEL IN THE 
BLOODSTREAM 
Insulin is an anabolic hormone produced by pancreatic β-cells. It is synthesised as pre-
proinsulin consisting of three peptide chains: the acidic A chain and the basic B chain, which 
are connected through C peptide. Pre-proinsulin is processed in the endoplasmic reticulum 
(ER) resulting in the formation of proinsulin. Proinsulin is folded in its 3D native structure 
and locked in this conformation by two disulphide bonds in the Golgi apparatus (GA) 
(Sanger, 1949; Weiss, 2009). Finally, proinsulin is cleaved and converted to insulin and C-
peptide by specific proteases, then subsequently stored in small granules and released into 
the bloodstream upon glucose or nutrient stimulation (Wilcox, 2005). Insulin is a member 
of a larger family and comprises insulin itself, insulin-like growth factors (IGF-I and IGF-
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II), relaxin peptides (relaxin-1, -2, and -3) and insulin-like peptides (INSL3, INSL4, INSL5, 
and INSL6) (Shabanpoor et al., 2009). 
 
Insulin has strong metabolic effects; it allows the cells to produce efficient energy reserves 
(ATP) through the absorption of glucose from the bloodstream and its subsequent 
metabolism allowing cells to survive and grow. The discovery of insulin is one of the biggest 
medical breakthroughs in history as it still remains the most used and proven therapy for the 
treatment of diabetes. However, fragile physical stability, and limited potency as well as 
adverse metabolic side-effects occurred in the past when using this hormone chronically. 
Based on these limitations, large improvements through biosynthesis of recombinant 
insulins with flexible pharmacokinetics was achieved in last decades (Mayer et al., 2007). 
Insulin production and secretion need to be tightly regulated since any misregulation leads 
to hypoglycaemia or hyperglycaemia. The concept and mechanism of glucose-stimulated 
insulin secretion from β-cells is well established (Schuit et al., 2001). Like any other cells in 
the body, β-cells uptake glucose by a specific family of receptors, called glucose 
transporters. There are two main constitutively expressed glucose transporters on the 
membrane surface in pancreatic β-cells in humans and rodents.  While major glucose 
transporter is glucose transporter type 2 (GLUT2) in rodents, human β-cells predominantly 
express glucose transporters type 1 and 3 (GLUT1 and 3) (Hiriart and Aguilar-Bryan, 2008). 
However, the uptake of glucose occurs after the glucose concentrations in circulating blood 
are higher than 2.5 mmol/L (Henquin, 2000). Once glucose enters the β-cells it is sensed by 
the key glyolytic enzyme glucokinase, which converts glucose to glucose-6-phosphate 
(G6P) (Wilcox, 2005). G6P is further metabolized through glycolysis and mitochondrial 
oxidation with ultimate production of ATP, resulting in a higher ATP to ADP ratio. High 
ATP levels then negatively regulate potassium-ATP-sensitive channels (K+ATP channels), 
which results in a closure of the K+ATP channels, leading to depolarization of the β-cell 
membrane. Depolarization stimulates opening of the voltage-dependent calcium channels 
(Ca2+ channels), Ca2+ entry, and subsequent elevation of intracellular Ca2+ concentration 
triggering exocytosis of the insulin granules into the bloodstream (Schuit et al., 2001) (Fig. 
2). Insulin secretion is pulsatile and biphasic, with a fast initial phase followed by a less 
intense and more extended second phase of secretion (Wilcox, 2005). After secretion into 
the blood-stream, insulin binds to the insulin receptor, expressed at the surface of metabolic 
tissues such as muscle and adipose stimulating glucose uptake by controlling GLUT4 
translocation from cytoplasm to the plasma membrane (Bryant et al., 2002). 
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Figure 2: Regulation of the insulin secretion in β-cell. Proper insulin secretion from -cells require precise 
nutrient sensing and signaling response. High ATP levels in the cell negatively regulate K+ATP channels, 
causing depolarization of the -cell membrane. This leads to opening of the Ca2+ channels and induction of 
insulin exocytosis in response to increased intracellular Ca2+ concentration (adapted from Ardestani et al., 
2017a). 
Slika 2: Uravnavanje izločanja inzulina v -celicah. Pravilno izločanje inzulina iz -celic zahteva natančno 
zaznavanje hranil in natančen odziv celičnih signalnih poti. Visoka koncentracija ATP povzroči zapiranje 
K+ATP kanalov, kar vodi v depolarizacijo -celične membrane. Posledično se odprejo Ca2+ kanali, ki omogočijo 
prehod Ca2+ ionov v celico. To povzroči izločanje inzulina s pomočjo eksocitoze (prirejeno po Ardestani in 
sod., 2017a). 
 
2.3 DIABETES MELLITUS  
Diabetes mellitus (DM) is a group of metabolic diseases, which result in elevated blood 
glucose level (hyperglycaemia). Chronic hyperglycaemia is associated with the long-term 
consequences of diabetes called “diabetes complications”, causing major public health 
problems, such as damage and dysfunction of the cardiovascular system, eyes, kidneys and 
nerves. Therefore, it contributes to the top five leading causes of death worldwide (Henry, 
1987). The prevalence of diabetes will be increased from 2.8% in year 2000 to 4.4% in year 
2030 for the age group of 20-79 years. Furthermore, the total number of people, suffering 
from diabetes was expected to rise from 171 million in 2000 to 366 million in 2030 (Wild et 
al., 2004); such prediction was even underestimated; currently, 422 million people suffer 
from diabetes (Global …, 2016). The occurrence of diabetes also varies between regions 
worldwide, with a very high progression in the developed countries (Global …, 2016). DM 
is divided in two main classes: type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus 
(T2D). T1D constitutes about 5-10% of the all individuals with diabetes although it is the 
major type of diabetes in children and young adults. It is linked to the autoimmune-mediated 
destruction of β-cells. T2D constitutes about 90-95% of all diabetes, which derives from 
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impaired β-cells function and mass in conjunction with insulin resistance (Wild et al., 2006; 
Alberti and Zimmet, 1998). 
2.3.1 Diabetes mellitus type 1 (T1D) 
 
T1D is the most common chronic autoimmune disease in the human childhood. First 
detectable initial symptoms for T1D occurrence are circulating antibodies against β-cell 
antigens before clinical manifestation of the disease (Pirot et al., 2008). The specific 
autoimmune destruction of pancreatic β-cells is characterised by abnormally infiltrated 
autoantibodies, that are crucial for β-cells autoimmunity (Knip and Siljander, 2008; Fu et 
al., 2013). Therefore, the occurrence of T1D is highly related to the invasion of immune cells 
including T cells (both CD4+ and CD8+ lymphocytes), B cells, natural killer cells and 
macrophages into the islets (Atkinson et al., 2011). Activated CD4+ T lymphocytes and 
macrophages are able to release pro-inflammatory cytokines such as tumor necrosis factor-
 (TNF-), interleukin-1β (IL-1β) and interferon- (IFN-), causing consequent β-cell death. 
Also, active islet-mediated production of cytokines and chemokines further enhances the 
migration of immune cells into islet proximity, which potentiates the deleterious interaction 
between β-cells and immune cells leading to β-cell destruction (Pirot et al., 2008). Additional 
mechanisms triggered by immune cells such as the perforin-dependent pathway or Fas/FasL-
mediated signaling are also actively involved in the process of β-cell destruction and loss of 
insulin production. It is important to note that both signaling pathways mediated by pro-
inflammatory cytokines/chemokines as well as β-cell-immune cell interactions initiate 
apoptotic death of pancreatic β-cells. The remaining populations of β-cells surviving from 
auto-immune attacks are thus unable to produce sufficient amounts of insulin to control 
blood glucose level, which leads to the development of T1D (Fu et al., 2013; Atkinson et al., 
2011). 
 
2.3.2 Diabetes mellitus type 2 (T2D) 
 
T2D is a systemic disorder of glucose homeostasis, where obesity is the leading pathogenic 
factor impairing insulin action (insulin resistance) and reducing functional β-cell mass 
mainly due to an increase in β-cell death (Atkinson et al., 2011). In an insulin resistance 
setting, metabolically active cells such as muscle and fat cells are not capable to properly 
respond to insulin and thus unable to clear glucose from the blood. In response to diminished 
insulin sensitivity, pancreatic β-cells consequently try to compensate with higher production 
of insulin by increasing their number (hyperplasia) and/or their size (hypertrophy). Although 
the blood glucose level may be higher than normal, it is still not meets the definition of T2D. 
This condition is called prediabetes and could last without any noticeable symptoms for 
years (Reaven, 1988; Samuel and Shulman, 2012). However, insulin resistance can 
eventually lead to T2D, when the β-cells fail to compensate for body's increased insulin 
demands. Obese individuals that are insulin resistant express higher levels of pro-
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inflammatory cytokines, especially interleukin-1β (IL-1β), which are the main cytokines, 
contributing to T2D development. This so-called low-grade systemic inflammation is a key 
pathogenic factor for development of T2D over time (Xu et al., 2003; Arkan et al., 2005). 
Although obesity may be the main reason for T2D development, around 80% obese people 
do not develop diabetes due to sustained compensatory action of healthy β-cells (Samuel 
and Shulman, 2012).    
 
2.4 PATHWAYS OF APOPTOSIS 
 
Apoptosis or programmed cell death is a highly regulated process, which controls cell 
homeostasis. It can be triggered by a wide range of exogenous and endogenous stimuli such 
as cytokines, radiation or apoptosis-inducing chemicals (Elmore, 2007). First morphological 
sign of apoptosis is cell shrinkage, where cells are smaller in size and cytoplasm is dense 
with tightly packed organelles. After extensive cell membrane “blebbing”, apoptotic bodies 
form, containing organelles and nuclear fragments. These bodies are eventually 
phagocytosed by immune cells and degraded. In apoptosis, an inflammatory reaction does 
not occur due to tightly closed apoptotic bodies by the intact plasma membrane, which 
prevents the release of the cell content into the surrounding tissue (Elmore, 2007).  
 
Apoptosis is regulated by different groups of enzymes, predominantly by caspases. These 
endoproteases are the main enzymes to initiate peptide bonds hydrolysation and thus 
inactivate crucial proteins for cell survival.  In later stages of apoptosis, mitochondria 
releases another group of pro-apoptotic proteins called endonucleases, which are 
translocated to the nucleus and cause DNA fragmentation and condensation of the chromatin 
(so-called karyopyknosis), leading to cell death (Elmore, 2007). Caspases are synthesised as 
pro-caspases and usually require additional cleavage or dimerization for their activation (Ura 
et al., 2001).  There are two different classes of caspases: initiator caspases and executioner 
caspases. Initiator caspases (caspase-8 and caspase-9) are activated by dimerization and 
usually function as a cleaving machinery for executioner caspases (caspase-3, caspase-6, 
caspase-7), which must be cleaved for their activation (McIlwain et al., 2013). 
 
The two well-established pathways of apoptosis are the intrinsic pathway (also called the 
mitochondrial pathway) and the extrinsic pathway (also called the death receptor pathway). 
Intrinsic pathway is initiated by cytokines, DNA or cytoskeletal damage, growth factor 
starvation, accumulation of unfolded proteins or other stressors (McIlwain et al., 2013).  For 
instance, in stressed β-cells exposed diabetogenic conditions such as high glucose, pro-
inflammatory cytokines, and oxidative stress, mammalian Sterile-20-like kinase 1 (MST1), 
a central component of Hippo signaling pathway, is activated. MST1 activation leads to 
activation of the stress kinase c-Jun N-terminal kinase (JNK) as well as inhibition of pro-
survival kinase AKT (Fig. 3). It should be noted that both JNK and AKT can regulate MST1 
activity through phosphorylation-dependent mechanisms. These events trigger the induction 
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of pro-apoptotic mitochondrial proteins BAX and BIM, together with decreasing anti-
apoptotic BCL-2 and BCL-xL levels (Fig. 3) (Ardestani et al., 2014; Anuradha et al., 2014; 
Ardestani and Maedler, 2016). Consequently, cytochrome C is released from the 
mitochondria and interacts with the adapter protein, called apoptotic protease-activating 
factor-1 (APAF1). APAF1 and pro-caspase-9 together with cytochrome C form a complex 
called apoptosome. Within the complex, APAF1 is now able to interact with pro-caspase-9, 
promoting dimerization and activation of caspase-9 in the cytosol. Active caspase-9 then 
initiates cleavage of executioner caspases such caspase-3, accelerating the induction and 
execution of apoptotic signaling down-stream of mitochondria. Differently from the intrinsic 
pathway, the extrinsic pathway is activated through the binding of exogenous ligands (such 
as fasL or TNFα) to the death receptors (such as FasR or TNFαR1). This leads to 
transduction of the signal through the plasma membrane and activation of adapter proteins 
Fas-associated death domain (FADD) or TNFR-associated death domain (TRADD). An 
activated adapter protein causes dimerization and activation of the initiator caspase-8, which 
can trigger apoptosis either directly by cleaving and activating executioner caspases or 
indirectly by cleavage of BID and triggering the intrinsic pathway of apoptosis (McIlwain 
et al., 2013). During apoptosis process, caspases can cleave enzymes involved in 
maintenance of DNA. One of such enzymes is a poly(ADP-ribose) polymerase (PARP), that 
is involved in the repair of single-strand DNA (SSD) brakes. Upon PARP cleavage by 
caspase-3, PARP is not able to bind to DNA strand brakes and is thus unable to signal the 
enzymatic machinery, responsible for SSD brakes repair. Additionally, cleavage and its 
subsequent inactivation of PARP is also required to maintain NAD+ in order to sustain ATP 
production, which is necessary for proper execution of energy (ATP)-dependent apoptosis 
process (Boulares et al., 1999). 
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Figure 3: Model of apoptotic signaling in β-cells. Diabetic stimuli lead to the activation of MST1, which 
upregulates mitochondrial pro-apoptotic BIM protein. By blocking the anti-apoptotic BCL-2 and BCl-xL 
proteins, BIM triggers BAX-dependent release of cytochrome c from mitochondria.  Cytochrome c binds to 
APAF1 and forms apoptosome, which cleaves and activates caspase-9. Active caspase-9 triggers cleavage of 
caspase-3, which further cleaves MST1 and induces β-cell apoptosis (adapted from Ardestani and Maedler, 
2017). 
Slika 3: Shematski prikaz apoptotičnega signaliziranja v β-celici. Diabetični dražljaj aktivira MST1, kar 
vodi v povišano izražanje mitohodrijskega pro-apoptotičnega BIM proteina. Ta prekine izražanje anti-
apoptotičnih BCL-2 in BCL-xL ter izloči citokrom c iz mitohondrija, v odvistnosti od BAX proteina. 
Citokrom c se pripne na APAF1 protein, s katerim tvori apoptosome kompleks. Slednji lahko cepi in 
aktivira protein kaspazo 9, ki dalje cepi kaspazo 3. Ta se lahko poveže v MST1 in z njegovo cepitvijo 
posledično sproži apoptozo β-celic (prirejeno po Ardestani in Maedler, 2017). 
 
2.5 SIGNAL TRANSDUCTION PATHWAYS IN DIABETES  
 
2.5.1 Hippo pathway 
The Hippo pathway was first discovered in Drosophila melanogaster and later extensively 
studied in mammalian cells (Meng et al., 2016).  This pathway plays a key role in organ size 
control and embryonic development through the regulation of cell proliferation, cell 
apoptosis and differentiation. It consists of a kinase cascade, transcriptional co-activators, 
and DNA-binding partners.  The main Hippo components include a mammalian Sterile-20-
like kinases 1 and 2 (MST1/2 /Hpo in Drosophila), large tumor suppressor 1 and 2 (LATS1/2 
/Warts in Drosophila) and two Yorkie (Yki) homologs YAP and TAZ transcriptional 
regulators (Saucedo and Edgar, 2007; Yuan et al., 2016a). Also, MST1/2 and LATS1/2 
require adapter proteins for their proper activation and signaling: Salvador 1 (Sav1) for 
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MST1/2 and Mps-one binder (MOB) kinase activator 1A and 1B (MOB1A/B) for LATS1/2 
(Yuan et al., 2016a). 
  
The Hippo pathway is active once Hippo up-stream regulator and adaptor protein the 
Neurofibromatosis 2 (NF2)/Merlin (Mer) directly initiates the activation of MST1/2-Sav1 
(James et al., 2009; Zhao et al., 2007). MST1/2-Sav1 complex phosphorylates and activates 
the LATS1/2 kinases, which together with MOB1, phosphorylate and inactivate 
transcriptional co-activators YAP and TAZ. LATS1/2 phosphorylation (I) exposes the 
docking site for binding to 14-3-3 proteins leading to YAP/TAZ cytoplasmic sequestration 
and (II) primes YAP/TAZ for additional phosphorylations by other kinases such as CK2, 
promoting their ubiquitin-proteasomal degradation (Lei et al., 2008; Ardestani and Maedler, 
2016).  In the absence of active MST1/2 and LATS1/2, YAP and TAZ are able to translocate 
into the nucleus. YAP and TAZ are unable to bind directly to DNA, thus they act mostly as 
transcriptional co-activators through association with several transcription factors mainly 
TEA domain (TEAD) family transcription factors, leading to YAP-TEAD complex 
formation and initiation of gene transcription mainly involved in regulation of proliferation, 
regeneration, survival and differentiation (Yuan et al., 2016a; Zhao et al., 2008) (Fig. 4). 
 
2.5.1.1 Mammalian Sterile-20-like kinases 1 and 2 (MST1/2) 
The Mammalian sterile-20-like (MST) kinase family is named for their similarity to the yeast 
Sterile-20-like and includes MST1, MST2, MST3, MST4 and YSK1 protein kinases. All 
five kinases can be divided into two groups, MST1/2 and MST3/4/YSK1 (Thompson and 
Sahai, 2015). Among these kinases, MST1/2 are core components in the Hippo pathway 
cascade and essential apoptotic molecules, which can regulate apoptosis under a wide range 
of stress stimuli including inflammatory cytokines, oxidative stress, high glucose and free 
fatty acids (FFA) (Yuan et al., 2016a; Ardestani and Maedler, 2016). The structural unit of 
MST1/2 comprises a N-terminal kinase catalytic domain, an auto-inhibitory domain, a 
SARAH domain, as well as specific caspase-cleavage sites (Thompson and Sahai, 2015). 
These caspase-cleavage sites are recognized by activated caspases, resulting in the removal 
of auto-inhibitory and SARAH domains and producing a highly active truncated form of 
MST1/2 during apoptosis. Uncleaved MST1/2 are mainly localized in the cytoplasm 
whereas the truncated form of MST1/2 translocates to the nucleus, where it can interact with 
new substrates, mainly transcription factors (Creasy et al., 1996; Lee et al., 2001). However, 
in response to apoptotic stimuli, MST1/2 need to be also autophosphorylated in the 
activation loop at Thr183, resulting in its activation. Activated MST1/2 together with adapter 
protein Sav1 and MST1-associated protein RASSF, stimulates apoptotic action through 
LATS1/2-YAP phosphorylation and phosphorylation of the other downstream substrates in 
the nucleus (Oh et al., 2006). One of the crucial MST1/2 substrates in the nucleus is H2B 
histone. MST1/2-induced H2B phosphorylation triggers chromatin condensation and cell 
death (Ardestani et al., 2014; Lee et al., 2001). As comprehensively reviewed by Rawat and 
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Chernoff, (2015) and Ardestani and Maedler (2016a), MST1/2 can interact and be regulated 
by a wide spectrum of other proteins including AKT, c-Abl, mTOR and PH domain and 
Leucine rich repeat Protein Phosphatases 1 and 2 (PHLPP1/2). AKT as well as mTOR can 
phosphorylate the C-terminus of MST1, to prevent caspase-mediated cleavage and its pro-
apoptotic action (Jang et al., 2007; Collak et al., 2012). In contrast, PHLPP1/2 function as 
MST1 endogenous activator by direct dephosphorylation of MST1 at the inhibitory site 
Thr387 that leads to MST1 activation and induction of apoptosis (Qiao et al., 2010). Because 
MST1/2 is an apoptotic activator, loss of MST1/2 kinases has been reported to lead to tissue 
overgrowth and tumor formation, causing lethality in early stages of the development (Lu et 
al., 2010).   
 
The kinase MST1 has an important role in the diabetic setting. MST1 is activated in the 
kidney of IRS2-KO diabetic mice (Carew et al., 2010), in epididymal fat of HFD-treated 
mice (Kawano et al., 2012) as well as in β-cells (Ardestani et al., 2014), cardiomyocytes 
(Zhang et al., 2016) and podocytes (Wu et al., 2016) under diabetic conditions, indicating 
its disease-associated hyper-activation during diabetes progression. Ardestani et al. (2014) 
have recently discovered that MST1 activation induces β-cell apoptosis and dysfunction and 
loss of MST1 markedly restores normoglycaemia, -cell function and survival in vitro and 
in vivo. Interestingly, transcription factor PDX1, which controls pancreas development, β-
cell viability as well as insulin gene transcription, is regulated by MST1. MST1 directly 
phosphorylates PDX1 at the evolutionary conserved site Thr11 under diabetic conditions. 
This mechanism leads to ubiquitin-mediated degradation of PDX1 and thus loss of insulin 
production and β-cell dysfunction. To confirm MST1 involvement in β-cell apoptosis, they 
additionally showed, that β-cell-specific disruption of MST1 in mice prevents 
hyperglycaemia, diabetes progression and β-cell death (Ardestani et al., 2014; Ardestani and 
Maedler, 2016). Our working group further confirmed, that MST1 inhibition improves β-
cells function and survival in human islets in vitro and in mice in vivo. Ardestani et al. 
(2017b) discovered a novel small molecule inhibitor of MST1, neratinib, as a potential drug 
in diabetes therapy to suppress β-cell apoptosis and restore normoglycaemia in both T1D 
and T2D diabetic mice. 
 
2.5.1.2 Yes-associated protein (YAP) 
 
YAP is a transcriptional co-activator consisting of two isoforms (YAP1 and YAP2), with 
anti-apoptotic and pro-proliferative function in variety of cell types, including β-cells (Yuan 
et al., 2016a) Both isoforms contain a proline-rich region, TEAD binding domain, SH3-
binding motif, transcriptional activation domain and PDZ domain-binding motif (Moroishi 
et al., 2015). LATS1/2-induced YAP phosphorylation on critical residues Ser127 and Ser381 
causes cytoplasmic retention as well as YAP degradation (Zhu et al., 2014). In contrast, 
unphosphorylated YAP is able to translocate into the nucleus, where it can interact with 
TEAD and other (RUNX, Smad1, and p73) transcription factor partners (Zhao et al., 2010). 
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Thus, YAP level and its cellular localization is crucial determinant factors for Hippo-
mediated proliferation and survival. Relevant to pancreatic β-cell, it has been shown that 
YAP is not expressed in human and mouse mature β-cells (Gao et al., 2014; George et al., 
2012). Re-expression of the constitutively active form YAP that is insensitive to LATS1/2 
inhibitory action effectively induces human β-cell proliferation and restores β-cell survival 
under multiple diabetic stimuli, including cytokines, oxidative stress or chronic high glucose 
treatments (Yuan et al., 2016a). 
 
 
 
Figure 4: The mammalian Hippo signaling. MST1/2, Sav1, LATS1/2, MOB1 and Yap/TAZ are the core 
components of the Hippo pathway. When the Hippo pathway is active (ON), NF2 and RASSF regulate MST1/2 
activity, which together with Sav1 phosphorylate and activates LATS1/2 kinases. Activated LATS1/2 
phosphorylate cytoplasmic YAP/TAZ, leading to 14-3-3 protein binding and ubiquitin-dependent degradation. 
MAP4Ks and NF2 may function as potent activators of LATS1/2. When Hippo is inactive (OFF), the 
unphosphorylated YAP/TAZ is translocated to the nucleus and binds to the TEAD family of transcription 
factors or other transcription factors, leading to the expression of target genes involved in cell survival and 
growth (adapted from Ardestani and Maedler, 2017).  
Slika 4: Hippo signalna pot pri sesalcih. MST1/2, Sav1, LATS1/2, MOB1 in Yap/TAZ so glavne komponente 
Hippo signalne poti. Ko je to signaliziranje “vključeno”, NF2 in RASSF uravnavajo aktivnost MST1/2, ki 
skupaj z Sav1 fosforilira in aktivira LATS1/2 kinaze. Aktiviran LATS1/2 fosforilira citoplazemski YAP/TAZ, 
kar pripelje do razgradnje YAP/TAZ, s pomočjo proteina 14-3-3. MAP4Ks in NF2 sta potencialna aktivatorja 
LATS1/2 kinaze. Ko je Hippo signalna pot “izključena”, lahko nefosforiliran YAP/TAZ preide v jedro in se 
veže z transkripcijskimi faktorji iz družine TEAD ali pa z drugimi transkripcijskimi faktorji. To vodi v začetek 
izražanja tarčnega gena, ki je vpleten v celično preživetje in rast (prirejeno po Ardestani in Maedler, 2017). 
2.5.2 IRS1/2-PI3K-AKT signaling  
 
Insulin signaling is a strictly regulated pathway, with a high specificity. It starts with binding 
of insulin to IR, which belongs to the subfamily of growth factor receptors tyrosine kinases 
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(RTKs). However, IR has a tetrameric structure and consists of two α subunits and two β 
subunits linked by disulphide bonds. In the presence of the insulin, it binds to the insulin-
binding domain of the α subunits. Then, activated IR initiates its enzymatic activity, resulting 
in auto-phosphorylation and increase in tyrosine phosphorylation of the β subunits. This 
leads to a phosphorylation cascade of a large number of its downstream targets, transducing 
extracellular signals into down-stream pathways (Becker and Roth, 1990). Other key 
components of insulin signaling are the insulin receptor substrates (IRS), with a main role 
to transfer signals from IR to the downstream molecules such as PI3K and AKT. IRS family 
has four different proteins: IRS1, IRS2, IRS3, and IRS4. However, IRS-1 and IRS-2 show 
the widest distribution in tissues. IRS-1 regulates glucose uptake, whereas IRS-2 is more 
related to mitogen-activated protein kinase (MAPK) signaling (Taniguchi et al., 2006). Since 
insulin signaling is the key pathway mediating metabolic and/or mitogenic effects of growth 
factors, it is crucial that this signaling is tightly regulated. Misregulation of insulin signaling 
is linked to a variety of pathological settings such as insulin resistance, diabetes or cancer 
(Poloz and Stambolic, 2015; Boucher et al., 2014).   
 
Upon insulin binding, IRS proteins are recruited and activated to further transduce signals 
to down-stream proteins. The phosphatidylinositol 3-kinase (PI3K) is a key signal 
transducing molecule for further substrate phosphorylation. A lipid kinase PI3K consists of 
a regulatory unit for IR binding, and a catalytic unit for phosphatidylinositol-4,5-biphosphate 
(PIP2) phosphorylation (Virkamäki et al., 1999; Raucher et al., 2000). The active PI3K 
recruits to the plasma membrane, where it can phosphorylate phospholipid PIP2. PIP2 is 
located on the plasma membrane and serves as carrier for interactions between plasma 
membrane and cytoskeleton. When phosphorylated, PIP2 is detached from the membrane 
and converted into phosphatidylinositol-3,4,5-triphosphate (PIP3), which serves as second 
messenger. PIP3 can directly bind to cytoplasmic proteins and recruits their substrates to the 
plasma membrane, where they can be further phosphorylated (Raucher et al., 2000). Since 
PIP3 is an important messenger and interacts with a large variety of downstream proteins, it 
is crucial that it is appropriately regulated. Any misregulation can lead in tumor growth and 
other pathological conditions (Chalhoub and Baker, 2009). Therefore, the PIP3/PIP2 ratio is 
strictly regulated by phosphatase and tensin homologue (PTEN), that dephosphorylates 
active PIP3 back to inactive PIP2 (Taniguchi et al., 2006).  
 
Further, PIP3 can directly bind and recruit pro-survival AKT/protein kinase B (PKB) to the 
plasma membrane. This prepares AKT for phosphorylation by upstream kinases PDK1 and 
mTORC2 (Newton and Trotman, 2014; Altomare and Testa, 2005). PDK1 starts 
phosphorylation on the activation loop at Thr308, followed by the phosphorylation at Ser473 
by mTORC2 (Martelli et al., 2012). AKT -to be fully active- requires both Thr308 and 
Ser473 phosphorylation (Gao et al., 2008). Once fully activated, AKT is locked in its active 
conformation and detached from the plasma membrane to diffuse through the cytosol and 
interact with its downstream targets (Newton and Trotman, 2014). In fact, AKT kinase is 
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one of the main intracellular protein to regulate cellular growth, survival and proliferation 
(Porta et al., 2014; Altomare and Testa, 2005). It is involved in many vital signaling 
pathways, such as regulation of mTORC1 activity, through inhibition of tuberous sclerosis 
complex 1 and 2 (TSC1/2) (Henry, 2003). In the absence of growth factors and nutrients 
stimulation, TSC1/2 negatively regulates mTORC1. In response to growth factors and 
nutrients stimulation, AKT directly phosphorylates TSC1/2 and inactivates its inhibitory 
action on mTORC1. Once activated, mTORC1 plays a crucial role in cell growth, protein 
synthesis and cell proliferation (Huang and Manning, 2010). There are several phosphatases 
acting on AKT in order to prevent its excessive function and to terminate its down-stream 
signaling. The threonine residue (Thr308) is dephosphorylated by protein phosphatase 2A 
(PP2A), whereas the serine residue (Ser473) is  dephosphorylated by PHLPP1/2 (PH domain 
and Leucine rich repeat Protein Phosphatases 1 and 2) (Martelli et al., 2012). 
2.5.3 PH domain and Leucine rich repeat Protein Phosphatases (PHLPP) 
 
PHLPP was discovered a little more than a decade ago in the rat hypothalamus and named  
suprachiasmatic nucleus (SCN) of circadian oscillatory protein (SCOP) (Shimizu et al., 
1999). It was observed that the expression levels of a SCOP’s mRNA are changed in 
response to the circadian rhythm (Hribal et al., 2015). SCOP protein was later renamed into 
PHLPP, after its domain characterization (PH domain and Leucine rich repeat Protein 
Phosphatases). Shortly after the discovery, Gao et al. (2005) showed that PHLPP acts as 
serine/threonine phosphatase targeting AKT for dephosphorylation. To date, only around 40 
serine/threonine phosphatases are known, compared to around 400 serine/threonine kinases. 
This suggests that phosphatases may dephosphorylate and regulate function of a wider range 
of their substrates, whereas kinases could be more specific, with a less variety in targets. The 
PHLPP protein family consists of two isoforms, PHLPP1 and PHLPP2, with a similar 
domain structure. PHLPP1 has two splice variants, where a smaller PHLPP1α has 1205 
amino acids and a larger PHLPP1β has 1717 amino acids. The second protein, PHLPP2 (also 
known as PHLPPL), consists of 1323 amino acids (Fig. 5). PHLPP1 and PHLPP2 are 
members of the protein phosphatase 2C (PP2C) family of serine/threonine phosphatases and 
together with others they form a metal-dependent protein phosphatase (PPM) family. 
Therefore, PPM phosphatase family requires two divalent cations, mostly magnesium 
(Mg2+) or manganese (Mn2+), for their activation (Grzechnik and Newton, 2016). 
 
PHLPP phosphatases act mostly through dephosphorylation of residues on the hydrophobic 
motif of their substrates in the cytosol, nucleus and mitochondria (Gao et al., 2005; Mathur 
et al., 2017). PHLPP has been shown as a critical regulator of cellular homeostasis. In 
particular, its dysregulation can lead to serious pathophysiological conditions such as cancer, 
obesity, diabetes or cardiovascular diseases (Qiao et al., 2010; Miyamoto et al., 2010; 
Andreozzi et al., 2011). The first identified PHLPP substrate was AKT, followed by many 
others, nicely described in the recent review by Mathur et al. (2017), e.g. protein kinase C 
(PKC), MST1, ribosomal protein S6 kinase 1 (S6K1), Raf1, and proteins of the MAPK 
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pathway (Grzechnik and Newton, 2016; Li et al., 2014). Gao et al. (2005) showed that 
PHLPP is able to negatively regulate mTORC2’s phosphorylation site, Ser473, on AKT by 
direct dephosphorylation. This will not completely inactivate AKT, but it would result in an 
around 20-fold lower activity compared to AKT phosphorylated on both, threonine and 
serine residues. Another study from Gao et al. (2008) has demonstrated that both, PHLPP1 
and PHLPP2 can dephosphorylate PKC. Elevated levels of PKC correlate with tumor growth 
and thus need to be strictly controlled. PHLPP1/2 dephosphorylate PKCβ on Ser660 and 
promote its downregulation by shunting PKC to the detergent-insoluble fraction of cells, 
where it will eventually be degraded. A recent study conducted by Li et al. (2014) 
characterized Raf1 as an another important PHLPP substrate. They showed that PHLPP 
negatively regulates Ras/Raf/MEK/ERK signaling by directly dephosphorylating Raf1, 
which inhibits its kinase activity. Ras/Raf/MEK/ERK signaling is important in cell growth 
and frequently de-regulated in cancer, making PHLPPs important novel suppressors of this 
pathway in the context of cell proliferation. Furthermore, the study from Liu et al. (2011) 
suggests that PHLPP is tightly regulated by mTOR activity. The mTOR inhibitor, 
rapamycin, negatively regulates PHLPP at the post-transcriptional level (Liu et al., 2010). 
 
PHLPP phosphatases are also involved in the regulation of critical pro-apoptotic MST1, and 
thus control apoptosis (Qiao et al., 2010; Ardestani et al., 2014). PHLPP directly 
dephosphorylates MST1 at inhibitory Thr387 site, leading to auto-phosphorylation of 
Thr183, which is important for MST1 activation and induction of apoptosis. This Thr387 
site is the common site of action for kinase AKT. AKT-induced MST1 phosphorylation at 
Thr387 inactivates MST1 and terminates apoptosis. Thus, PHLPP, AKT and MST1 
constitute a triangle signaling hub that regulates apoptosis in a tightly controlled manner 
(Qiao et al., 2010).  
 
 
Figure 5: PHLPP1/2 protein structure. The structural unit of PHLPPs contain a Ras association (RA) domain, 
a pleckstrin homology (PH) domain, a series of leucine-rich repeats (LRR), a protein phosphatase domain 
(PP2C) and a PDZ binding motif toward the C terminal (adapted from Mathur et al., 2017).  
Slika 5: Struktura proteina PHLPP1/2. PHLPP proteini so strukturno zgrajeni iz Ras association (RA) 
domene, pleckstrin homology (PH) domene, serij sekvenc bogatih z levcinom (LRR), proteinsko fosfatazne 
domene (PP2C) in iz PDZ-binding motif na C terminalu (prirejeno po Mathur in sod., 2017). 
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2.5.4 Mammalian target of rapamycin (mTOR)  
 
Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase, a nutrient-
responsive regulator of proliferation, growth and metabolism in the cell (Blandino-Rosano 
et al., 2012; Leibowitz et al., 2008). mTOR forms two structurally and functionally distinct 
complexes; mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Both proteins 
are structured in a very complex manner, with multiple associated proteins, where mTOR, 
Raptor, PRAS40, Deptor, and mLST8/GL form mTORC1, and mTOR, mLST8/GL, 
Deptor, Rictor, mSin1, and Protor form mTORC2. mTORC1 is activated by growth factors 
(insulin and IGF-1), nutrients (amino acids, glucose), as well as by high energy status 
(elevated ATP/AMP ratio) in the cell, whereas mTORC2 exclusively by growth factors, such 
as insulin and IGF-1 (Laplante and Sabatini, 2012). The importance of mTOR has been first 
identified through the use rapamycin, an allosteric inhibitor of mTOR (Blandino-Rosano et 
al., 2012). Namely, acute rapamycin treatment is primarily known for its anti-growth and 
anti-proliferative effects, which blocks mTORC1 by interacting with a FK506-binding 
protein (FKBP12). In contrast, chronic exposure to rapamycin disrupts mTORC1 together 
with mTORC2 and inhibits AKT survival activity in cells (Laplante and Sabatini, 2012; 
Barlow et al., 2012). Rapamycin has been widely used to investigate mTOR function in 
various tissues including pancreatic islets (Fraenkel et al., 2008). Although mTORC1 seems 
to be more directly involved in protein synthesis and anabolic cell growth, mTORC2 also 
regulates cell proliferation and survival as well as cytoskeleton dynamics and organization 
by phosphorylating downstream kinases such as AKT, SGK1 and PKC (Saxton and Sabatini, 
2017). 
 
Stimulus-induced mTORC1 activation switches cellular metabolism from catabolism to 
growth-promoting anabolic metabolism initiating the synthesis of proteins, lipids and 
nucleotides, which require considerable amounts of energy (Laplante and Sabatini, 2012). 
In order to do that, growth factors and amino acids need to activate mTORC1, to affect cell 
growth and proliferation (Elghazi et al., 2006). Amino acid-dependent stimulation of 
mTORC1, where leucine and arginine are especially important, converts the Rag GTPases 
to an active state, allowing them to bind Raptor and recruit mTORC1 to the lysosomal 
membrane, near to Rheb, where it can be activated. It is suggested that the main purpose of 
amino acid signaling may be co-localization of mTORC1 with its activator Rheb (Bar-Peled 
and Sabatini, 2014; Saxton and Sabatini, 2017). However, in the absence of Rags, mTORC1 
is not able to translocate to the surface of lysosome and stays inactivated. Since mTORC1 
activation requires activated Rags and activated Rheb, it is necessary that both, amino acid 
and growth factor signaling is available (Saxton and Sabatini, 2017).   
In growth factor-dependent stimulation, mTORC1 activity is positively regulated by protein 
kinase AKT through phosphorylation of 40kDa Pro-rich AKT substrate (PRAS40) and 
TSC1/2. Namely, PRAS40 specifically targets and inhibits mTORC1 activity when cells are 
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under energy or nutrient starvation.  In the presence of growth factor and high nutritional 
state, AKT directly inactivates PRAS40 by direct phosphorylation, leading to the elevation 
of mTORC1 activity (Elghazi et al., 2006). However, mTORC1 is also negatively regulated 
through the TSC1/2 complex. When TSC1/2 is active, it stimulates GTP hydrolysis and 
inactivates Rheb, an endogenous activator of mTORC1, and consequently mTORC1. In 
contrast, mTORC1 is activated when AKT phosphorylates and inactivates the TSC1/2 
complex (Inoki et al., 2003). TSC1/2 phosphorylation and inactivation by AKT, releases the 
inhibition of Rheb, leading to activation of mTORC1 and cell growth (Inoki et al., 2003; 
Chong-Kopera et al., 2006).  
mTORC1 positively regulates protein synthesis through promoting translation initiation by 
modulating mRNA translation, through phosphorylation of ribosomal protein S6 kinase 1 
(S6K1), and eukaryotic initiation factor 4E binding protein 1 (4E-BP1) (Hay and Sonenberg, 
2004; Arsham et al., 2003; Gingras et al., 1999). This results in dissociation of 4E-BP1 from 
the key initiation factor eukaryotic translation initiation factor 4E (eIF4E), allowing it to 
participate in the formation of the eIF4F complex, which specifically promotes cap-
dependent translation. mTORC1-dependent phosphorylation of S6K1 activates S6K1 to 
phosphorylate several substrates such as ribosomal protein S6 (a component of the 40S 
ribosomal subunit), protein synthesis initiation factor 4B (elF4B), and elongation factor 2 
kinase (eEF2K), which also promotes translation initiation and elongation (Sonenberg and 
Hinnebusch, 2009; Holz et al., 2005). In contrast, in the lack of stimulation by nutrients or 
growth factors, both, S6K1 and 4E-BP1 stay unphosphorylated. Consequently, 4E-BP1 
remains attached to the translational machinery and thus blocks protein synthesis (Gingras 
et al., 1999). However, mTORC1 is also able to control growth and proliferation indirectly 
through mTORC1-S6K1-mediated negative feedback loops, which negatively regulate 
mTORC2-AKT signaling arm as well as IRS1/2. These negative loops cause long-term 
compensatory mechanisms, resulting in inhibition of AKT and suppression of pro-survival 
signaling (Le Bacquer et al., 2007; Yuan et al., 2016b). 
 
Since mTORC1 signaling modulates protein synthesis and thus cell growth in various types 
of cells, it is also described as a key positive regulator of β-cell growth, proliferation, and 
survival (Yuan et al., 2016b; Magnuson et al., 2012). In the context of β-cells, Balcazar et 
al. (2009) showed that mTORC1 is a major regulator of cell cycle progression by modulating 
cyclin D2, D3 and Cdk4 activity in β-cells (Fig. 6). In addition to the beneficial impact of 
mTORC1 on β-cell growth, proliferation and survival at normal physiology, mTORC1 is 
constitutively hyper-activated at high nutritional context relevant to obesity and T2D. 
Several lines of evidence showed that mTORC1 activity is increased in islets and β-cells 
cultured under T2D mimic conditions such as high glucose and high free fatty acid as well 
as in isolated islets from mouse models of T2D; high-fat-treated mice and leptin-receptor 
deficient db/db mice (Vernier et al., 2012; Bachar et al., 2009; Mir et al., 2015). Yuan et al., 
(2016b) demonstrated that mTORC1 is also hyper-activated in islets and β-cells isolated 
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from T2D patients compared to healthy individuals and its genetic or pharmacological 
inhibition improved insulin secretion in the human and mouse T2D islets.    
 
 
Figure 6: mTOR signaling in -cells. Growth factors (insulin or IGF-1) and glucose regulate mTORC1 
through the PI3K-AKT-TSC-Rheb signaling arm, whereas nutrients, such as amino acids, function through the 
Rag family of GTPase. mTORC2 is mainly activated by extracellular stimuli such as growth factors and 
together with AKT promotes β-cell survival, insulin secretion, and β-cell adaptation through the 
phosphorylation of key down-stream substrates. Growth factor-dependent AKT activation stimulates GTPase 
Rheb by inhibiting the TSC1/2. Amino acids-dependent activation of mTORC1 involves the lysosomal Rag 
GTPases and the recruitment of mTORC1 to the lysosomal membrane to stimulate mTORC1, which can 
through phosphorylation of the S6K1 and the 4E-BP1 controls anabolic growth and mRNA translation. 
Activated S6K1 further phosphorylate ribosomal protein S6 and promotes protein synthesis. A master cellular 
energy sensor, AMPK, senses a drop in ATP/AMP ratio and inactivates mTORC1. Additionally, mTORC1 
modulates cyclin D2, D3, and Cdk4 activity in β-cells and regulates cell cycle progression (adapted from Amin 
Ardestani et al., 2017a). 
Slika 6: mTOR signaliziranje v -celicah. Rastni faktorji (inzulin ali IGF-1) in glukoza uravnavajo izražanje 
mTORC1 preko PI3K-AKT-TSC-Rheb signalne poti. Hranila kot so amino kisline pa uravnavajo mTORC1 
preko GTP-az iz družine Rag. mTORC2 je v glavnem aktiviran preko rastnih faktorjev in skupaj z AKT 
proteinom omogoča β-celično preživetje, izločanje inzulina in njihovo pravilno delovanje preko fosforilacije 
drugih pomembnih proteinov. Aktivacija AKT preko rastnih faktorjev stimulira GTP-azo Rheb preko 
inhibitornega delovanja na TSC1/2. Ko je mTORC1 aktiviran preko amino kislin se ta s pomočjo Rag GTP-
aze veže na membrano lizosoma in preko S6K1 in 4E-BP1 uravnava rast celice in translacijo mRNK. Aktiviran 
S6K1 fosforilira ribosomalni protein S6 in omogoči začetek sinteze proteinov. AMPK je v celici zadolžen za 
zaznavanje razmerja ATP/AMP. Ko je to razmerje nizko, AMPK inaktivira mTORC1. Prav tako je mTORC1 
sposoben tudi regulirati ciklina D2, D3 in aktivnost Cdk4 v β-celicah in s tem uravnavati celični cikel (prirejeno 
po Amin Ardestani in sod., 2017a) 
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
 
3.1.1 Chemicals 
 
 2-merkaptoethanol (Sigma-Aldrich, USA) 
 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Sigma-Aldrich, USA) 
 Bicine (Sigma-Aldrich, USA) 
 Bis-Tris (Sigma-Aldrich, USA) 
 Bovine Serum Albumine (BSA) (Sigma-Aldrich, USA) 
 dCTP, dGTP, dTTP, dATP (TermoFisher Scientific, USA) 
 Diethylpyrocarbonate (DEPC) (Sigma-Aldrich, USA) 
 Direct PCR-Tail peqGOLD (VWR, USA) 
 DNA StainG (Serva, USA) 
 DreamTaq Buffer 10x (TermoFisher Scientific, USA) 
 DreamTaq DNA polymerase (TermoFisher Scientific, USA) 
 Ethanol (Sigma-Aldrich, USA) 
 Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, USA) 
 Extracellular matrix (ECM)-coated dishes (Novamed, Israel) 
 Fatal Calf Serum (FCS) (Biochrom GmbH, Germany) 
 Gentamycine Sulfate Solution – 50 mg Gentamycine SO4/mL in water (Gemini Bio-
products, USA) 
 Glucose (Braun, Germany) 
 Glycogen (TermoFisher Scientific, USA) 
 Halt Proteinase and Phosphatase Inhibitor cocktail (PPI) (TermoFisher Scientific, USA) 
 Histopaque-1077 (Sigma-Aldrich, USA) 
 Histopaque-1119 (Sigma-Aldrich, USA) 
 Igepal CA-630 (Sigma-Aldrich, USA) 
 Immobilon Western Chemiluminescent HRP substrate (Milipore, Germany) 
 Insulin ELISA (ALPCO, USA) 
 LE Agarose (Biozym, Germany) 
 MassRuler DNA ladder (TermoFisher Scientific, USA) 
 MassRuler DNA loading dye 6x (TermoFisher Scientific, USA) 
 Methanol (VWR, USA) 
 Mouse insulin ELISA (ALPCO, USA) 
 Nonfat dry milk (Biozym, Germany) 
 NuPage 4-12% Bis-Tris Gel (Life Technologies, USA) 
 NuPage Antioxidant (Life Technologies, USA) 
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 NuPage LDS sample buffer 4x (Life Technologies, USA) 
 ON-TARGETplus siRNA (Dharmacon, USA) 
 PageRuler Plus Prestained Protein Ladder 250 kDa and 170 kDa (TermoFisher 
Scientific, USA) 
 Paraformaldehyde (PFA) (Sigma-Aldrich, USA) 
 Pierce BCA Protein Assay Kit (TermoFisher Scientific, USA) 
 Polyvinylidene difluoride (PVDF) membrane (Carl Roth, Germany) 
 RNaseZAP (Sigma-Aldrich, USA) 
 Sodium azide (NaN3) (Sigma-Aldrich, USA) 
 Sodium hydrogencarbonate (bicarbonate) NaHCO3 (Sigma-Aldrich, USA) 
 Sodium chloride NaCl (Carl Roth, Germany) 
 Sodium Dodecyl Sulfate (SDS) (PanReac AplliChem, USA) 
 Sodium hypochloride solution (12% Cl) (Carl Roth, Germany) 
 Tween-20 (Sigma-Aldrich, USA) 
 Ultrasensitive insulin ELISA (ALPCO, USA) 
 
3.1.2 Laboratorial equipment 
 
 Biological safty cabinet MSC Advantage (TermoFisher Scientific, USA) 
 Camera E.A.S.Y. 429K (Herolab, Germany) 
 Centrifuge 5415R (Eppendorf, USA) 
 Centrifuge 5810R (Eppendorf, USA) 
 Centrifuge Heraeus Megafuge 16R (TermoFisher Scientific, USA) 
 Electrophoresis chamber XCell SureLock minicell (Invitrogen, USA) 
 Electrophoresis EV243 and EV245 (AlphaMetrix, USA) 
 Falcon tubes (Sarstedt, Germany) 
 Fluid aspirator BVC 21 (Vacuubrand, USA) 
 Fluid aspirator N811KN (KNF Laboport, USA) 
 Freezer Ultra low VIP series (Sanyo, Japan) 
 Incubator Heraeus Function Line (TermoFisher Scientific, USA) 
 Incubator New Brunswick Galaxy 170S (Eppendorf, USA) 
 Microplate reader Infinite F200 pro (TECAN, Switzerland 
 Microscope AE2000 (Motic, Hong Kong) 
 Mixer and heater RH basic KT/C (IKA, Germany) 
 PeqLAB peqPETTE pipettes (0,5-10 ul, 2-20 ul, 10-100 ul, 20-200 ul, 100-1000 ul) 
(VWR, USA) 
 Real-Time PCR Applied Biosystems StepOne Plus system (Applied Biosystems, USA) 
 Refrigerator (Liebherr, Germany) 
 Scale PL83-S/03 classic light (Mettler Toledo, USA) 
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 Shaker DRS-12 (Neolab, Germany) 
 Shaking water bath Termolab 1083 (GFL, Germany) 
 Spectrophotometer NanoDrop ND-1000 (TermoFisher Scientific, USA) 
 Suspension dishes (Sarstedt, Germany) 
 Thermocycler PCR peqSTAR 96 universal gradient (VWR, USA) 
 Thermo shaker HLC HMR 11 (Ditabis, Germany) 
 Transiluminator (Herolab, Germany) 
 Vortex RS-VA 10 (Phoenix technologies, USA) 
 Western blot camera Imaging System W/Biochemi HR (UVP, USA) 
 
3.1.3 Buffers and solutions 
 
 1x Krebs-Ringer hydrogencarbonate buffer (KRB): 10x KRB, 0.5% BSA, 5 mM 
NaHCO3, 20 mM HEPES, dH2O 
 Blocking buffer: 2.5% non-fat dry milk, 2.5% BSA, TBS-T 
 Hank's Balanced Salt Solution (HBSS) (Lonza, Switzerland) 
 Kreb's Ringer Buffer (KRB): 135 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.4 mM 
K2HPO4, 5.5 mM Glucose, 20 mM HEPES, dH2O 
 NuPage MES SDS Running Buffer 20x (Life Technologies, USA) 
 Phosphate-Buffered Saline (PBS): 137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 2mM 
KH2PO4, dH2O 
 Primary antibody buffer solution: 5% BSA, 0.1% sodium azide, TBS-T 
 Quenching buffer: 10x HBSS, 20 mM HEPES, 1% BSA, 0.035% NaHCO3, dH2O 
 Radioimmunoprecipitation assay (RIPA) buffer: 150 mM sodium chloride, 1.0% Igepal 
CA-630, 0.5% sodium deoxycholate, 0.1% SDS (sodium dodecyl sulfate), 50 mM Tris, 
pH 8.0 
 Secondary antibody buffer solution: 2.5% non-fat dry milk, TBS-T 
 Transfer buffer 20x SDS-PAGE: 500 mM Bis-Tris, 20.5 mM EDTA, 500 mM Bicine, 
dH2O 
 Transfer buffer working solution: 5% transfer buffer, 0.1% antioxidant, 20% methanol, 
dH2O 
 Tris-acetate-EDTA (TAE) buffer: 40 mM Tris, 20 mM Acetate, 1mM EDTA, dH2O 
 Tris-Buffered Saline (TBS): 50 mM Tris-HCl, 150 mM NaCl, dH2O 
 Tris-Buffered Saline + Tween20 (TBS-T): 0.1% Tween20, TBS 
 
3.1.4 Culture medium 
 
 RPMI-1640 11.1 mmol/L glucose (Roswell Park Memorial Institute medium 1640) 
(Lonza, Switzerland) 
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 RPMI-1640 mouse islets complete media: RPMI-1640 media, 10% FCS, 0.1% 
gentamycine 50 mg/mL, 0.1% fungizide, 1% penicillin-streptomycine 
 RPMI-1640 INS-1E complete media: RPMI-1640, 10% FCS, 1% penicillin-
streptomycine, 1% HEPES, 1% Sodium pyruvate, 50 µM -merkaptoethanol 
 RPMI-1640 INS-1E starvation media: RPMI-1640, 1% penicillin-streptomycine, 1% 
HEPES, 1% Sodium pyruvate, 50 µM -merkaptoethanol 
 CMRI-1066 5.5 mmol/L glucose (Connaught Medical Research Laboratories medium-
1066) (Invitrogen, USA) 
 CMRI-1066 complete media: CMRI-1066 media, 10% FCS, 0.1% gentamycine, 0.1% 
fungizide, 1% penicillin-streptomycine 
 CMRI-1066 starvation media: CMRI-1066 media, 0.1% gentamycine, 0.1% fungizide, 
1% penicillin-streptomycine 
 DMEM (Dulbecco's Modified Eagle Medium) (Sigma-Aldrich, USA) 
 DMEM complete media: DMEM media, 10% FCS, 1% penicillin-streptomycine, 2 mM 
L-glutamine 
 Ca2+ - KRH medium: KCl 4.74 mmol/L, KH2PO4 1.19 mmol/L, MgCl2+6H2O 1.19 
mmol/L, NaCl 119 mmol/L, CaCl2 2.54 mmol/L, NaHCO3 25 mmol/L and HEPES 10 
mmol/L 
 
3.1.5 Enzymes 
 
 Liberase TM (Collagenase I and Collagenase II) (Roche, Switzerland) 
 
3.1.6 Inhibitors 
 
 Neratinib (Calibr, USA) 
 Rapamycin (Calbiochem, USA) 
 Ribosomal protein S6 kinase 1 selective inhibitor (S6K1i) PF-4708671 (Calbiochem, 
USA)  
 
3.1.7 Activators 
 3-BDO (3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one)) (J&K 
Scientific, China) 
3.1.8 Vectors 
 
 Ad-h-PHLPP2 (ADV-214159) (Vector Biolabs, USA) 
 Ad-h-HA-PHLPP1b (Vector Biolabs, USA) 
 Ad-CMV-b-gal/LacZ (Vector Biolabs, USA) 
 
Lupše B. Identification of signaling pathways controlling survival of pancreatic β-cells in diabetes.  
 M. SC. Thesis. Ljubljana, Univ. of Ljubljana, Biotechnical Faculty, Academic Study of Biotechnology, 2017 
24 
3.1.9 Primary antibodies 
 
 Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb 
 Cleaved PARP (Asp214) (D64E10) XP Rabbit mAb 
 GAPDH (D16H11) XP® Rabbit mAb 
 Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb 
 Phospho-AKT (Ser473) (D9E) XP Rabbit mAb 
 Phospho-NDRG1 (Thr346) (D98G11) XP Rabbit mAb 
 Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit mAb 
 Phospho-S6 Ribosomal Protein (Ser235/236) (D57.2.2E) XP® Rabbit mAb 
 YAP Antibody Rabbit pAb  
 β-Actin (13E5) Rabbit mAb 
 β-Tubulin (9F3) Rabbit mAb 
All from Cell Signaling Technology, USA. 
 
 Anti-FLAG Rabbit pAb (Sigma-Aldrich, USA) 
 Anti-PHLPP1 rabbit pAb (PRX-MKA0606AF) (Cosmo, Japan) 
 PHLPP2 Antibody A300-661A Rabbit pAb (Bethyl, USA) 
 Phospho anti-MST1/MST2 (T183) antibody (ab79199) (Abcam, UK) 
 
3.1.10 Secondary antibodies 
 
 Peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L) (Jackson 
ImmunoResearch, USA) 
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3.2 METHODS 
 
3.2.1 Mice  
 
We used C57BL/6J mice for high-fat/high sucrose diet (HFD) experiments originally 
derived from Jackson Laboratory, USA. They were fed with HFD (Surwit Research Diets, 
New Brunswick, USA), containing 58%, 26% and 16% calories from fat, carbohydrate and 
protein for 17 weeks. Their littermates were fed with normal diet (ND) (Harlan Teklad 
Rodent Diet 8604, Envigo, UK) containing 12.2%, 57.6% and 30.2% calories from fat, 
carbohydrate and protein for the same time. Heterozygous leptin receptor deficient mice on 
the C57BLKS/J background (Leprdb/+, db/+), were also provided by Jackson Laboratory, 
USA. Through breeding, diabetic Leprdb/db (db/db) and non-diabetic heterozygous Leprdb/+ 
(db/+) mice were obtained.  After 17 weeks of HFD or at the age of 12 weeks (db/db), islets 
were isolated as described below. Animals were housed in a temperature-controlled room 
with a light-dark cycle of 12:12 h. They had free access to food and water, in agreement with 
the EU and the US National Institutes of Health animal care guidelines and the German 
animal protection law and approved by the Bremen Senate. 
 
3.2.2 Mouse islets isolation  
 
After 17 weeks of HFD or at the age of 12 weeks (db/db), mice were killed.  In the safety 
cabinet, mouse abdomen was opened in an inverted T-shape. After injection to the common 
bile duct, 2 mL of ice-cold Liberase solution (Liberase TM Collagenase I and Collagenase 
II, Roche, Switzerland) were further injected into the pancreas: the part attached to the 
intestine and the part attached to the spleen. Pancreases were separated from internal organs 
and placed in pre-chilled Falcon tubes including 0.5 mL Liberase solution. They were 
incubated and digested in a pre-heated shaking water bath at 37°C for 10 minutes. Once 
digested, tubes were washed with Quenching buffer and centrifuged in pre-chilled centrifuge 
(Heraeus Megafuge 16R) at 1200 rpm, 4°C for 5 minutes with 3 repetitions. Afterwards, 13 
mL of Histopaqu-1077 and Histopaque-1119 (ratio 1:1) (Sigma-Aldrich, USA) mixture was 
added in tubes, followed by adding 12 mL cold 1xHBSS, in order to make gradient layers. 
Tubes were then centrifuged at 4°C and 500 g, with slow acceleration and no brake for 25 
minutes. All next steps were performed in biological safety cabinet (MSC Advantage). 
Floating islets were hand-picked from the interface layer between 1xHBSS media and 
Histopaque with a transfer pipette into a new Falcon tube. Islets were then washed with 
RPMI-1640 (Lonza, Switzerland) and centrifuged for 15 minutes at 2000 rpm, 4°C. Islets 
were re-suspended in pre-heated (37°C) RPMI-1640 mouse islets complete media, 
transferred in 3 cm suspension dishes and incubated (incubator New Brunswick Galaxy 
170S) at 37°C and 5% CO2. 
 
 
Lupše B. Identification of signaling pathways controlling survival of pancreatic β-cells in diabetes.  
 M. SC. Thesis. Ljubljana, Univ. of Ljubljana, Biotechnical Faculty, Academic Study of Biotechnology, 2017 
26 
3.2.3 Human islets culture  
 
Human islets were isolated from pancreases of healthy donors and patients with T2D at the 
University of Illinois at Chicago (USA), Geneva University (Switzerland), Leiden 
University (Belgium), Lille University (France) and at ProdoLabs (USA). When provided, 
human islets were cultured in our lab on extracellular matrix (ECM)-coated dishes or 
suspension dishes in CMRI-1066 (Invitrogen, USA) complete media with 5.5 mM glucose, 
at 37°C and 5% CO2 (incubator New Brunswick Galaxy 170S). Informed consent was 
obtained from all subjects. Ethical approval for the use of human islets had been granted by 
the Ethics Committee of the University of Bremen.  
3.2.4 INS-1E cells culture 
 
The clonal insulinoma rat -cell line INS-1E was provided by C. Wollheim, University of 
Geneva (Switzerland) and Lund University (Sweden). INS-1E cells were cultured in RPMI-
1640 INS-1E complete media and regularly split, once confluency in tissue-culture dishes 
reached 80-90%. 
 
3.2.5 MEF TSC2-/- cells culture 
 
MEF TSC2-/- cells were generously provided by Gil Leibowitz, Hadassah-Hebrew 
University Medical Center (Israel). MEF TSC2-/- cells were cultured in DMEM complete 
media and regularly split, once confluency in tissue-culture dishes reached 80-90%. 
 
3.2.6 Adenoviral overexpression of PHLPP 1 and 2 in islets and INS-1E cells  
 
Islets or INS-1E cells were infected (transducted) with adenoviruses carrying LacZ (ad-
CMV-b-gal/LacZ), as control, PHLPP1 (ad-h-HA-PHLPP1b) and PHLPP2 (ad-h-PHLPP2) 
(all from Vector Biolabs, USA) in starvation media (CMRI-1066 starvation media for human 
islets, and RPMI-1640 INS-1E starvation media for INS-1E cells). Islets/INS-1E cells were 
then incubated for 4 hours at 37°C and 5% CO2, washed with PBS and replaced by 2 mL 
fresh complete media (CMRI-1066 complete media for human islets, and RPMI-1640 INS-
1E complete media for INS-1E cells). Infected islets or INS-1E cells were cultured for 48 
hours at 37°C and 5% CO2. 
 
Virus volumes were calculated by the following equation (1): 
 
𝑉𝑖𝑟𝑢𝑠 𝑣𝑜𝑙𝑢𝑚𝑒 (µ𝐿) =
𝑀𝑂𝐼 ∗ 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
𝑡𝑖𝑡𝑒𝑟 (𝑃𝐹𝑈/𝑚𝐿)
      ... (1)  
 
- Number of cells       200 000 – 3 000 000 cells  
- Multiplicity of Infection (MOI)     20 - 100 
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- Titer: 
o ad-h-HA-PHLPP1b    2,3x1010 PFU/mL 
o ad-h-PHLPP2    4,6x1010 PFU/mL 
o ad-CMV-b-gal/LacZ   1,0x1010 PFU/mL 
 
 
3.2.7 Inhibitor treatment of islets, INS-1E and MEF TSC2-/- cells 
 
Human and mouse islets, INS-1E cells and MEF TSC2-/- cells were cultured with 10 µmol/L 
S6K1 selective inhibitor PF-4708671, 100 nmol/L rapamycin (both from Calbiochem, USA) 
or 10 µmol/L neratinib (Calibr, USA) in complete media (RPMI-1640 mouse complete 
media for mouse islets, CMRI-1066 complete media for human islets, RPMI-1640 INS-1E 
complete media for INS-1E cells, DMEM complete media for MEF TSC2-/- cells) for 24 
hours at 37°C and 5% CO2. 
 
3.2.8 Transfection of human islets for raptor knock down 
 
To knock down Raptor expression in human islets, SMARTpool technology (Dharmacon, 
USA) was used. A mix of ON-TARGETplus siRNAs directed against human raptor 
(sequences UGGCUAGUCUGUUUUCGAAA, CACGGAAGAUGUUCGACAA, 
AGAAGGGCAUUACGAGAUU and UGGAGAAGCGUGUCAGAUA; 100 nmol/L)) was 
transfected into human islets. An ON-TARGETplus non-targeting siRNA pool served as -
control. Islets were dispersed with accutase (PAA) to break islets into smaller cell aggregates 
to increase transfection efficiency and cultured on ECM dishes for 1 day. Isolated islets were 
exposed to KRH transfection medium. After 1 hour incubation, lipoplexes (Lipofectamine 
2000/siRNA ratio 1:20 pmol) were added to transfect the islets cells with additional 5-6 
hours incubation. Transfected human islets were cultured in CMRL-1066 medium 
containing 20% FCS and L-glutamine (Ardestani et al., 2014).  
 
3.2.9 Glucose stimulated insulin secretion (GSIS) 
 
To observe acute insulin secretion in response to glucose concentrations, human islets were 
first washed with PBS and pre-incubated in Krebs-Ringer hydrogencarbonate buffer (KRB), 
pH 7.4, containing 2.8 mM glucose for 30 minutes. Afterwards, islets were incubated in 
fresh KRB with 2.8 mM glucose (marked as basal) for 1 hour, followed by incubation in 
16.7 mM glucose KRB buffer (marked as stimulated) for an additional 1 hour. Insulin 
content was then determined by human insulin ELISA kit (ALPCO, USA), according to the 
manufacturer’s instructions. The absorbance was measured with a microplate reader (Infinite 
F200 pro) at 450 nm. Secreted insulin was normalized to insulin content, which was 
extracted from lysed islets as described in 3.2.10. 
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3.2.10 Protein extraction and protein concentration measurement 
 
Incubated islets or cells were washed with PBS and lysed with radioimmunoprecipitation 
assay (RIPA) lysis buffer, which was supplemented with Protease and Phosphatase Inhibitor 
cocktail (100x) (ThermoFisher, USA). Islet or cell lysates were frozen at -80°C and thawed 
at room temperature (RT) for the three cycles. Once scraped off the culturing dishes, they 
were transformed into 1.5 mL tubes, put on ice and repetitively vortexed. Samples were then 
centrifuged (Centrifuge 5415R) for 20 minutes at 13200 rpm and the supernatant was 
transferred into new tubes. Protein concentration was determined according to the 
manufacturer’s instructions with the Pierce BCA protein assay kit (TermoFisher Scientific, 
USA). The absorbance was measured on microplate reader (Tecan, Infinite F200 pro) at 560 
nm. Protein samples were stored at -80°C. 
 
3.2.11 Electrophoresis and Western Blot 
 
For each western blot sample preparation equivalent concentrations from each treated 
sample were mixed together with demineralised water, NuPage 4x loading dye (Invitrogen, 
USA) and 2-mercaptoethanol as reducing agent (Sigma-Aldrich, USA). Samples were 
incubated for 10 minutes at 95°C. For electrophoretic running buffer NuPage 20x MES SDS 
running buffer (Invitrogen, USA) was used, diluted in demineralised water together with 
NuPage antioxidant (Invitrogen, USA). Samples were run on NuPage 4-12% Bis-Tris gels 
(Invitrogen, USA) together with a specific PageRuler protein ladder (Invitrogen, USA), 
using electophoretic chambers XCell SureLock (Invitrogen, USA) and EV243 or EV245 
electrophoresis (AlphaMetrix, USA). After electrophoresis gels were transfered onto PVDF 
membranes, which had been activated in 100% methanol and washed in demineralised 
water. For protein transfering from gels into membranes, electroelution or electrophoretic 
transfer were used because of simplicity and transfer efficiency. XCell II blot module 
cassettes and XCell SureLock chambers in combination with EV243 or EV245 
electrophoresis were used. Afterwards PVDF membranes were blocked with 2,5% BSA and 
2,5% non-fat dry milk, with gently shaking at 12 rpm (shaker DRS-12) for 1 hour. 
Membranes were incubated overnight (4°C, 12 rpm), with the following primary antibodies: 
Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb, Cleaved PARP (Asp214) (D64E10) XP 
Rabbit mAb, GAPDH (D16H11) XP® Rabbit mAb, Phospho-4E-BP1 (Thr37/46) (236B4) 
Rabbit mAb, Phospho-AKT (Ser473) (D9E) XP Rabbit mAb, Phospho-NDRG1 (Thr346) 
(D98G11) XP Rabbit mAb, Phospho-p70 S6 Kinase (Thr389) (108D2) Rabbit mAb, 
Phospho-S6 Ribosomal Protein (Ser235/236) (D57.2.2E) XP® Rabbit mAb, YAP Antibody 
Rabbit pAb, β-Actin (13E5) Rabbit mAb, β-Tubulin (9F3) Rabbit mAb (all from Cell 
Signaling Technology, USA), Phospho anti-MST1/MST2 (T183) antibody (ab79199) 
(Abcam, UK), Anti-PHLPP1 Rabbit pAb (PRX-MKA0606AF) (Cosmo, Japan) and anti- 
PHLPP2 Antibody A300-661A Rabbit pAb (Bethyl, USA). Primary antibodies were 
prepared in primary antibody buffer solution all diluted 1:1000. For secondary antibody 
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incubation, Peroxidase-conjugated Goat Anti-Rabbit IgG (Jackson ImmunoResearch, USA) 
was used, (1:10 000 in 5 % non-fat dry milk solution) for 1 hour, at room temperature. 
Finally, membranes were developed using chemiluminiscence Immobilon Western 
Chemiluminescent HRP substrate (Merck Millipore, USA) together with analysis software 
VisionWorksLS (UVP, USA). 
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4 RESULTS 
 
4.1 CHAPTER 1: HIPPO PATHWAY 
 
4.1.1 Neratinib, a novel MST1 inhibitor protects pancreatic β-cells in diabetes  
 
Since the identification of MST1 as a key regulator of pancreatic -cell death and 
dysfunction in diabetes by the Islet Biology Lab at University of Bremen (Ardestani et al., 
2014), an interdisciplinary project consisting of chemists at Calibr institute (USA), -cell 
biologists at the Islet Biology Laboratory, and Mass Spec specialists at the MALDI lab, 
University of Bremen, has been established to identify a novel, potent and specific small 
molecule inhibitor for MST1. A high throughput MST1 inhibition screen has been 
performed across a highly-privileged collection of 641 drug-like kinase inhibitors together 
with a triaging strategy for selective, non-cytotoxic compounds that could potently inhibit 
kinase MST1. We identified neratinib, currently in Phase III clinical trials for breast cancer 
targeting Her2/EGFR dual kinases, as a novel small molecule inhibitor of MST1 (Ardestani 
et al., 2017b). In this study, MST1 inhibition by neratinib restores normoglycaemia and 
improves β-cell survival and function in both T1D and T2D mouse models as well as in 
human islets and the -cell line INS-1E (Ardestani et al., 2017b). 
 
In my part, I have tested whether neratinib can inhibit stress-induced MST1-activation and 
-cell apoptosis in isolated human islets and the established -cell line, INS-1E. Several 
conditions of a complex diabetic milieu including pro-inflammatory cytokines (mixture of 
interleukin-1β and interferon-γ), increased glucose concentrations alone or in combination 
with free fatty acid palmitic acid or H2O2 as an oxidative stress model were applied. 
Apoptosis was measured by determining cleavage of caspase-3 (readout for caspase-3 
activation) and poly-(ADP-ribose) polymerase (PARP), a downstream substrate of caspase-
3. In INS-1E cells exposed to diabetogenic conditions, neratinib fully blocked MST1 
autophosphorylation (represented by T183 phosphorylation) and substantially reduced 
caspase-3 and PARP cleavage (Cl Casp3 and Cl PARP) at both tested, 5 and 10 μM 
concentrations (Fig. 7A-C) (Ardestani et al., 2017b). Also, MST1 inhibition by neratinib 
greatly restored PDX1 (-cell specific MST1 substrate) level under diabetic high glucose 
condition (Fig. 7C). Consistently, neratinib treatment suppressed MST1 activation and 
induction of caspase-3 cleavage triggered by pro-inflammatory cytokines as well as 
glucolipotoxic conditions in primary human islets (Fig. 7D,E) (Ardestani et al., 2017b). 
These data suggest that neratinib is a potential -cell protective compound by inhibiting 
stress-induced MST1 activation. 
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Lupše B. Identification of signaling pathways controlling survival of pancreatic β-cells in diabetes.  
 M. SC. Thesis. Ljubljana, Univ. of Ljubljana, Biotechnical Faculty, Academic Study of Biotechnology, 2017 
32 
 
 
 
 
 
 
 
Figure 7: Neratinib treatment inhibits MST1 activation and apoptosis in human islets and INS-1E cells. 
INS-1E cells were cultured in 22.2 mM glucose (HG), 22.2 mM glucose and 0.5 mM palmitic acid (HG/Palm) 
for 72h or exposed to oxidative stress with H2O2 for 6h (A-C).  Human islets were exposed to 22.2 mM glucose 
and 0.5 mM palmitic acid (HG/Palm) or mixture of cytokines (interleukin-1β and interferon γ; IL-1β+IFNγ) 
for 72h (D, E). Neratinib was added in culturing media in concentrations from 5-10 µM for INS-1E cells and 
from 10-25 µM for human islets. Phosphorylated MST1 (pMST1), cleaved caspase-3 (Cl Casp3), cleaved 
PARP (Cl PARP) and PDX1 were analyzed by western blotting. Actin, GAPDH or Tubulin were used as 
loading controls. 
Slika 7: Tretiranje človeških Langerhansovih otočkov in INS-1E celic z neratinibom blokira aktivnost 
MST1 in posledično apoptozo. INS-1E celice so bile izpostavljene 22.2 mM glukozi (HG), 22.2 mM glukozi 
v kombinaciji z palmitinsko kislino (HG/Palm) za 72 ur ali pa izpostavljene oksidativnemu stresu z H2O2 za 6 
ur (A-C). Človeški Langerhansovi otočki so bili izpostavljeni 22.2 mM glukozi v kombinaciji z palmitinsko 
kislino (HG/Palm) ali pa mešanici citokinov (interleukin-1β and interferon γ; IL-1β+IFNγ) za 72 ur (D, E). 
Neratinib je bil dodan v medij v koncentraciji 5-10 µM za INS-1E celice in v koncentraciji 10-25 µM za 
človeške Langerhansove otočke. Fosforiliran MST1 (pMST1), cepljena kaspaza-3 (Cl Casp3), cepljen PARP 
(Cl PARP) in PDX1 so bili analizirani z western blotom. Aktin, GAPDH ali tubulin so bili uporabljeni kot 
kontrola. 
 
 
 
 
 
 
 
D 
E 
Human islets 
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4.1.2 Proproliferative and anti-apoptotic action of exogenously introduced YAP in 
pancreatic β cells  
 
Another key component of the Hippo pathway, transcription co-activator YAP regulates the 
expression of genes mainly involved in proliferation and survival in various cell types (Hill 
et al., 2015). Several lines of evidence showed that YAP expression decreases during 
pancreas development and its expression switched off in mature primary human or mouse 
pancreatic endocrine cells including β-cells (George et al., 2012). Lack of YAP expression 
may explain the extremely low-rate of β-cell replication and the limited β-cell regenerative 
potential. To test whether islet-specific induction of YAP can promote β-cell proliferation 
and viability, our working group has re-expressed a constitutively active form of YAP 
(YAPS127A; with a serine 127 to alanine substitution) in human islets as well as in INS-1E 
cells. For overexpression, we used adenoviruses expressing luciferase (Ad-Luc) as control 
or constitutively active YAP (Ad-YAP; insert pCMV-flag YAPS127A), in order to prevent 
MST/LATS-mediated YAP inactivation. Our data showed that YAP overexpression 
remarkably induces human β-cell proliferation without impairing insulin secretion as well 
as protects human islets and INS-1E cells from apoptosis under multiple diabetic conditions 
(Yuan et al., 2016a). Further mechanistic data showed elevation of transcription factor 
forkhead box M1 (FOXM1) at mRNA and protein level in human islets. FOXM1 inhibition 
abolished its proliferative potential, indicating that YAP-induced β-cell proliferation is 
FOXM1-dependent (Yuan et al., 2016a).   
 
My contribution to this study was to test the pro-survival effect of YAP re-expression in 
INS-1E cells and human islets exposed to diabetogenic conditions such as chronically 
increased glucose concentrations (glucotoxicity), its combination with palmitic acid 
(glucolipotoxicity), pro-inflammatory cytokines interleukine-1β (IL-1β) and interferon-γ 
(IFN-γ), and H
2
O
2
 as a model of oxidative stress. YAP overexpression markedly decreases 
caspase-3 and PARP cleavage (Cl Casp3 and Cl PARP) in INS-1E cells under all listed 
diabetic conditions (Fig. 8A-C) (Yuan et al., 2016a) . In line with INS-1E cell experiments, 
adenoviral-mediated YAP overexpression decreases cytokines- and glucolipotoxicity-
induced caspase-3 activation in three independent isolated human islet preparations (Fig. 9) 
(Yuan et al., 2016a). These data show the pro-survival function of exogenously introduced 
YAP in both a β-cell line and primary human islets. 
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Figure 8: The anti-apoptotic effect on YAP overexpression in INS-1E cells (published in Yuan et al. (2016a)). 
INS-1E cells were transfected with control GFP or with YAP overexpressing plasmid, and treated to mimic diabetic 
conditions. The treatments were: mixture of pro-inflammatory cytokines IL-1β and IFN-γ for 48h (A), 22.2 mM 
glucose (22.2) or the mixture of 22.2 mM glucose and 0.5 mM palmitic acid (22.2Palm) for 48h (B), and 25 μM 
H2O2 for 5h (C). For all conditions, YAP overexpression was checked together with cleaved caspase-3 (Cl Casp3) 
and cleaved PARP (Cl PARP) protein levels and normalized on Actin, GAPDH or Tubulin housekeeping gene. 
Slika 8: Anti-apoptotični učinek povečanega izražanja YAP proteina v INS-1E celicah (objavljeno v Yuan in 
sod., (2016a)). INS-1E celice so bile transformirane z GFP ali z plazmidom za povečano izražanje YAP proteina. 
Bile so tretirane z: mečanico pro-inflamatornih citokinov IL-1β in IFN-γ za 48 ur (A), 22.2 mM glukozo (22.2) ali 
pa 22.2 mM glukozo v kombinaciji z 0.5 mM palmitinsko kislino (22.2Palm) za 48 ur (B), in 25 µM H2O2 za 5 ur 
(C). Za vse vzorce je bilo poleg povečanega izražanja YAP analizirana tudi cepljena kaspaza-3 (Cl Casp3) in 
cepljen PARP (Cl PARP). Aktin, GAPDH ali tubulin so bili uporabljeni kot kontrola.  
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Figure 9: YAP-overexpressing protected human islets from apoptosis (published in Yuan et al. (2016a)). 
Human islets were infected with control adenovirus expressing luciferase (Ad-Luc) or with adenovirus 
overexpressing YAP (Ad-Flag-YAP). Islets were treated with mixture of pro-inflammatory cytokines IL-1β 
and IFN-γ (5.5IL/IF) (A) or the mixture of 22.2 mM glucose and 0.5 mM palmitic acid (22.2Palm) (B) for 3 
days. For all conditions, a cleaved caspase-3 (Cl Casp3) protein level was checked and normalized on Actin 
housekeeping loading control. For YAP detection, an anti-flag antibody was used. Data are from three 
independent experiments from three different islet donors (#1 - #3). 
Slika 9: Povečano izražanje YAP varuje človeške Langerhansove otočke pred apoptozo (objavljeno v 
Yuan in sod., (2016a)). Človeški Langerhansovi otočki so bili okuženi z adenovirusom, ki vsebuje luciferazo 
kot kontrolo (Ad-Luc) in adenovirusom, ki vsebuje YAP za povečano izražanje (Ad-Flag-YAP). 
Langerhansovi otočki so bili tretirani z mečanico pro-inflamatornih citokinov IL-1β in IFN-γ (5.5IL/IF) (A) 
ali pa z 22.2 mM glukozo v kombinaciji z 0.5 mM palmitinsko kislino (22.2Palm) (B) za 3 dni. Za vse vzorce 
je bilo analizirano izražanje cepljene kaspaze-3 (Cl Casp3), aktin pa je služil kot kontrola. Za detekcijo YAP 
proteina je bilo uporabljeno anti-flag protitelo. Podatki so bili analizirani iz treh neodvisnih poskusov s tremi 
različnimi darovalci Langerhansovih otočkov (#1 - #3). 
  
A B 
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4.2 CHAPTER 2: MAMMALIAN TARGET OF RAPAMYCIN (mTOR) 
 
4.2.1 Reciprocal regulation of mTOR complexes in pancreatic islets from humans 
with type 2 diabetes  
 
mTOR complex 1 (mTORC1) is the main nutritional sensor, with high importance in cell 
metabolism, proliferation and survival. Therefore, it is not surprising, that its dysregulation 
contributes to the pathogenesis of variety of diseases, including diabetes (Lamming et al., 
2012; Efeyan and Sabatini, 2010). In recent published study, our working group 
demonstrated, that the mTORC1 is highly upregulated in pancreatic islets of obese diabetic 
mice, in human islets chronically exposed to high glucose concentrations as well as in islets 
and β-cells isolated from human individuals with T2D (Yuan et al., 2016b). In contrast, 
mTOR complex 2 (mTORC2) is declined in high glucose-treated human islets and in islets 
of T2D patients (Yuan et al., 2016b).  
 
My work was to test the effect of mTORC1-S6K1 signaling inhibition using novel selective 
S6K1 inhibitor cell-permeable piperazinyl pyrimidine compound (PF-4708671) as well as 
siRNA against raptor, a key component of mTORC1, on insulin secretion in islets isolated 
from diabetic mice and human islet from individuals with T2D. S6K1 is one of the main 
mTORC1 substrate, involved in the negative feedback loops that block mTORC2-AKT 
activation (Efeyan and Sabatini, 2010). Therefore, we hypothesized that S6K1 inhibition 
may diminish mTORC1’s negative impact on β-cell function and mTORC2-AKT axis. For 
that, we analysed if diminished mTORC2 can be restored, once mTORC1 is inhibited in 
human and mouse diabetic islets. Western blot analysis showed successful inhibition of 
mTORC1-S6K1 signaling and restored mTORC2 activity in primary human and mouse 
diabetic islets (Fig. 10A,B). This was represented by diminished phosphorylation of S6K1’s 
substrate ribosomal protein S6 at Ser235/236 (pS6) (mTORC1 readout) and by restoration 
of mTORC2 downstream target AKT at Ser473 (pAKT) (mTORC2 readout) in human islets 
(Fig.10A). In islet isolated from HFD-treated mice, S6K1 inhibitor also dramatically blocked 
pS6 signals together with up-regulation of mTORC2 signaling, with higher phosphorylation 
of pAKT and other mTORC2 down-stream target such as NDRG1 at Thr346 (pNDRG1) 
(Fig. 10B) (Yuan et al., 2016b). 
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Figure 10: S6K1 inhibition restores mTORC2 signaling in the diabetic islets (published in Yuan et al. 
(2016b)). Human islets isolated from three T2D donors (A) and islets from high-fat-died (HFD) mice (B) were 
checked for activated mTORC1 and activated mTORC2. mTORC1 activity is represented by pS6, whereas the 
mTORC2 activity is represented by pAKT and pNDRG1. Human and mice islet samples were untreated or 
acutely exposed (4h) to the 10 µM S6K1 inhibitor (S6K1i). Actin or GAPDH were used as loading controls. 
Slika 10: Inhibicija S6K1 obnovi mTORC2 signaliziranje v diabetičnih Langerhansovih otočkih 
(objavljeno v Yuan in sod., (2016b)). Človeški langerhansovi otočki iz treh različnih darovalcev s SBT2 (A) 
in Langerhansovi otočki iz miši, ki so bile hranjene z visoko vsebnostjo maščob (HFD) (B) so bili analizirani 
za stopnjo aktivnosti mTORC1 in mTORC2. mTORC1 aktivnost je bila ponazorjena z pS6 proteinom, 
mTORC2 aktivnost pa z pAKT in pNDRG1. Človeški in mišji Langerhansovi otočki so bili netretirani ali pa 
tretirani z S6K1 inhibitorjem (S6K1i) za 4 ure. Aktin ali GAPDH sta bila uporabljena kot kontrola. 
 
We also performed selective inhibition of mTORC1 by direct targeting its main component 
raptor. Inhibition was achieved by small interfering RNA (siRNA)-mediated silencing of 
raptor with non-targeting siRNA (siScr) as a control. Raptor knockdown resulted in decrease 
in mTORC1 activity and impaired phosphorylation of pS6K1, pS6 and p4E-BP1 in human 
islet donors with T2D (Fig. 11) (Yuan et al., 2016b). Our data show that both 
pharmacological (using S6K1 inhibitor) as well as genetic (using siRNA against raptor) 
suppression of mTORC1-S6K1 signaling improved insulin secretion in isolated islets from 
HFD-treated mice and T2D patients (Yuan et al., 2016b). 
A 
B 
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Figure 11: siRNA-mediated silencing of raptor resulting in mTORC1 inhibition (published in Yuan et al. 
(2016b)). In order to observe mTORC1 silencing, T2D human islets were transfected with non-targeting siRNA 
(siScr) and siRNA against raptor (siRaptor). Samples were run by western blotting and checked for raptor 
protein expression together with pS6K1, pS6, p4E-BP1. Actin was used as loading control. Both lanes were 
run on the same gel but were non-contiguous. 
Slika 11: Utišanje raptorja z siRNK povzroči zmanjšano izražanje mTORC1 (objavljeno v Yuan in sod., 
(2016b)). Da bi lahko ponazorili zmanjšano izražanje mTORC1 so bili človeški Langerhansovi otočki z SBT2 
transfektirani z ne-tarčno siRNK (siScr) in siRNK proti raptorju (siRaptor). Vzorci so bili analizirani z western 
blotom za izraženost raptor proteina skupaj z pS6K1, pS6, p4E-BP1. Aktin je bil uporabljen kot kontrola. Obe 
liniji sta bili analizirani na istem blotu a ne zaporedno. 
  
Human islets 
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4.3 CHAPTER 3: PH DOMAIN AND LEUCINE RICH REPEAT PROTEIN 
PHOSPHATASES 1 AND 2 (PHLPP1/2) 
 
As discussed previously, Hippo kinase MST1 is a fundamental regulator of the apoptotic 
pathway and causes pancreatic -cell death under diabetic conditions (Ardestani et al., 
2014). Therefore, we searched for endogenous up‐stream molecules, that are able to activate 
MST1. Phosphatases PHLPP1/2 were identified as such molecules that dephosphorylate and 
activate MST1 under diabetic conditions, which results in increased apoptosis and 
consequently decreased -cell survival (Ardestani et al., unpublished data). In addition to 
MST1, PHLPP1/2 dephosphorylates and inactivates pro-survival kinase AKT at Ser473 site 
(Gao et al., 2005). In order to investigate the role of PHLPP1/2 phosphatases under diabetic 
conditions, I have performed several experiments in cell lines, primary mouse and human 
islets as well as islets isolated from diabetic mice.   
 
4.3.1 Upregulation of PHLPP1/2 in mouse models of T2D 
 
To confirm PHLPP1/2 upregulation in diabetes, we used db/db (Leprdb/db ) mice as a rodent 
T2D model in which diabetes was caused by a spontaneous genetic mutation of the leptin 
gene (Tartaglia, 1997), and mice fed with HFD for 17 weeks. Western blots analysis showed 
that PHLPP1 and PHLPP2 are markedly upregulated in diabetic db/db and HFD mice, 
compared to their respective control (Fig. 12A,B). PHLPPs up-regulation was correlated 
with hyperactivation of mTORC1 through increased pS6K1, pS6,  and p4E-BP1 in isolated 
islets from db/db and HFD  mice. In contrast, mTORC2 activity was diminished, shown by 
decreased phosphorylation of NDRG1 (pNDRG1) at Thr346 or phosphorylation of AKT 
(pAKT) at Ser473. NDRG1 cannot be directly phosphorylated by mTORC2. Activation of 
mTORC2 leads to phosphorylation and activation of SGK1 at Ser422, which can 
phosphorylate its downstream target NDRG1 (Saxton and Sabatini, 2017). Furthermore, I 
confirmed increased apoptotic signaling in diabetic db/db and HFD mice, represented by the 
increase in te phosphorylated form of MST1 (pMST1) at Thr183, which is critical for its 
activity (Fig. 12A,B). 
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Figure 12: PHLPP1/2 upregulation in Leprdb/db and HFD mouse models of T2D. Islet lysate from db/db 
(A) and HFD (B) mice and their respective controls were run on western blot and checked for PHLPP1, 
PHLPP2, pMST1, pS6K1, pS6, pNDRG1 and p4E-BP1. One batch of islets from db/db (A) and two batches 
of islets from HFD (B) are shown. Actin was used as loading control. Both lanes were run on the same gel but 
were non-contiguous (HFD batch 2). 
Slika 12: Povečano izražanje PHLPP1/2 v Leprdb/db and HFD mišjih modelih za SBT2. Lizati 
Langerhansovih otočkov iz db/db (A) in HFD miši (B) ter njihovih kontrol so bili analizirani z western blotom 
za izraženost PHLPP1, PHLPP2, pMST1, pS6K1, pS6, pNDRG1 in p4E-BP1. Prikazana je ena serija 
Langerhansovih otočkov iz db/db (A) in dve serije iz HFD (B) miši. Aktin je bil uporabljen kot kontrola. Obe 
liniji sta bili analizirani na istem blotu, vendar ne zaporedno (HFD batch 2). 
 
A 
B 
HFD batch 1 HFD batch 2 
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4.3.2 mTORC1 regulates PHLPP levels 
 
4.3.2.1 Study in MEF TSC2-/- cells 
 
PHLPPs up-regulation is correlated with mTORC1 hyper-activation in diabetic islets (see 
Fig. 12) and it has been previously shown that the expression of PHLPP1/2 is controlled by 
mTORC1 at protein translation levels in non-β-cells (Liu et al., 2010). To confirm whether 
mTORC1 regulates PHLPP level, we used mouse embryonic fibroblasts (MEF) isolated 
from tuberous sclerosis complex 2 knock-out (TSC2-/-) mice. MEF TSC2-/- cells are a well 
established cellular model with constitutive hyperactivation of mTORC1 due to the lack of 
its endogenous inhibitor, TSC2 (Henry, 2003). Such hyper-activation was documented 
through increased phosphorylation of mTORC1 down-stream targets S6K1, S6 and 4E-BP1 
(Yuan et al., 2016). In order to block mTORC1, MEF TSC2-/- cells were treated with 100 
nM rapamycin. Successful inhibition of mTORC1 by rapamycin was shown through 
decreased pS6K1, and pS6. In line with data presented in the previous chapter in diabetic 
islets, mTORC1 inhibition also restored mTORC2 activity here in MEF TSC2-/- cells as 
shown by increased in levels of pAKT and pNDRG1. Notably, mTORC1 inhibition 
diminished expressions of both PHLPP isoforms suggesting mTORC1-dependnet regulation 
of PHLPP1/2 (Fig. 13). 
 
 
 
Figure 13: mTORC1 regulates PHLPP1/2 expression in MEF TSC2-/- cells. MEF TSC2-/- cells were 
treated without or with 100 nM rapamycin (Rapa) for 24h. PHLPP1, PHLPP2, pS6K1, pS6, p4E-BP1 and 
pNDRG1 protein levels were analyzed by westen blot. Two different experimental replicates were run. Actin 
was used as loading control. 
Slika 13: mTORC1 uravnava izražanje PHLPP1/2 v MEF TSC2-/- celicah. MEF TSC2-/- celice so bile 
tretirane brez ali z 100 nM rapamicinom (Rapa) za 24 ur. Izražanje PHLPP1, PHLPP2, pS6K1, pS6, p4E-BP1 
in pNDRG1 je bilo analizirano z western blotom. Vzorci so bili v dveh ponovitvah, aktin pa je služil kot 
kontrola.  
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4.3.2.2 Pharmacological activation of mTORC1 
 
To confirm mTORC1-dependent PHLPP up-regulation, we directly activated mTORC1 in 
the INS-1E and in human islets using pharmacological tool. We have used cell permeable 
small molecule activator of mTORC1 3-Benzyl-5-((2-nitrophenoxy)methyl)-dihydrofuran-
2(3H)-one (3-BDO), which activates mTORC1 through competitively binding of FK506-
binding protein 1A (FKBP1A) at the same site as rapamycin and thereby activating 
mTORC1 (Peng et al., 2014). Activation of mTORC1 was confirmed after treatment of INS-
1E cells and human islets by 3-BDO, as represented by western blot analysis of mTORC1 
down-stream targets pS6K1, pS6 and p4E-BP1. Also, 3-BDO markedly increased the protein 
expression of PHLPP1/2 together with pMST1 and caspase-3 cleavage (Cl Casp3) (Fig. 14). 
These data confirm that mTORC1 positively regulates intracellular level of PHLPPs. 
 
 
 
 
 
 
Figure 14: mTORC1 activation by 3-BDO up-regulates PHLPPs. INS-1E cells were treated with 10 µM 3-
BDO or left untreated for 6h (A), whereas human islets were treated with 20 µM 3-BDO for 2 days (B). 
PHLPP1, PHLPP2, pMST1, pS6K1, pS6, p4E-BP1 and Cl Casp3 protein levels were analyzed by westen blot. 
Actin was used as loading control. 
Slika 14: Aktivacija mTORC1 z 3-BDO poveča izražanje PHLPP proteinov. INS-1E celice so bile tretirane 
brez ali z 10 µM 3-BDO za 6 ur (A). Človeški Langerhansovi otočki pa so bili tretirani z 20 µM 3-BDO za 48 
ur (B). Oba lizata sta bila analizirana z western blotom za izražanje PHLPP1, PHLPP2, pMST1, pS6K1, pS6, 
p4E-BP1 in Cl Casp3. Aktin je bil uporabljen kot kontrola.  
 
  
B A 
Lupše B. Identification of signaling pathways controlling survival of pancreatic β-cells in diabetes.  
 M. SC. Thesis. Ljubljana, Univ. of Ljubljana, Biotechnical Faculty, Academic Study of Biotechnology, 2017 
43 
4.3.2.3 mTORC1 inhibition reduced PHLPP level in T2D 
 
Raptor was silenced to test whether mTORC1 inhibition also regulates PHLPPs in T2D 
islets. mTORC1 inhibition was achieved by siRNA-mediated silencing of raptor (siRaptor). 
Raptor deficiency impaired the phosphorylation of mTORC1 targets S6K1, S6 and 4E-BP1 
in human islet donors with T2D (Fig. 15) (Yuan et al., (2016). Raptor silencing also highly 
decreased both PHLPP1 and PHLPP2 levels compared to siScr-treated diabetic islets as a 
control. This further confirms PHLPPs regulation by mTORC1 signaling in samples isolated 
from T2D patients. 
 
 
 
Figure 15: siRNA-mediated silencing of raptor reduced PHLPPs in T2D islets. Islets isolated from human 
T2D were transfected with raptor siRNA (siRaptor) or non-targeting siRNA (siScr) for 2 days. PHLPP1, 
PHLPP2, pS6K1, pS6, p4E-BP1 and raptor protein levels were analyzed by western blot. Blots were collected 
from two independent human islets preparations. Actin was used as loading control. Raptor, pS6K1, pS6, 
p4EBP1 and actin (lower panel) are re-used from Fig. 11, which was published before (Yuan et al., 2016). 
Slika 15: Utišanje raptorja na račun siRNA zmanjša izražanje PHLPP proteinov v Langerhansovih 
otočkih z SBT2. Langerhansovi otočki, ki so bili izolirani iz človeških trebušnih slinavk z SBT2, so bili 48 ur 
transfektirani z siRNK proti raptorju (siRaptor) ali z ne-tarčnim siRNK (siScr). PHLPP1, PHLPP2, pS6K1, 
pS6, p4E-BP1 in raptor so bili analizirani z western blotom. Bloti so bili zbrani iz dveh ločeno pripravljenih 
lizatov človeških Langerhansovih otočkov. Aktin je bil uporabljen kot kontrola. Raptor, pS6K1, pS6, p4EBP1 
in aktin (spodnji del) so ponovno uporabljeni iz Slike 11, ki je bila tudi predhodno objavljena v znanstvenem 
članku (Yuan in sod., 2016). 
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4.3.3 PHLPPs impair glucose-stimulated insulin secretion (GSIS) in human islets 
 
To check whether PHLPP overexpression is detrimental for β-cell function, we 
overexpressed PHLPP1/2 in human islets through adenovirus transduction, which efficiently 
up-regulated PHLPPs in our system. The ability of acute insulin response was tested in non-
diabetic human islets, in response to different glucose concentrations, where 2.8 and 16.7 
mM glucose represented basal and stimulated insulin secretion respectively. Overexpression 
of PHLPPs were sufficient to impair β-cell function in isolated human islets overexpressing 
both PHLPP1 and PHLPP2 compared to LacZ control infected-human islets (Fig. 16) 
suggesting its negative effect on β-cell insulin secretion.  
 
 
 
 
 
 
Figure 16: PHLPP1/2 overexpression diminished glucose-stimulated insulin secretion. Human islets were 
transduced with PHLPP 1 and PHLPP2 or LacZ adenoviruses. Insulin secretion was measured after 1h 
incubation, with 2.8 mmol/L (white bars, basal insulin) and additional 1h with 16.7 mmol/L glucose (grey bars, 
stimulated insulin), and normalised to insulin content (A). The insulin stimulatory index showing the ratio 
between stimulated (16.7 mmol/L) and basal (2.8 mmol/L) insulin secretion (B). The result from one human 
islets preparation is shown.  
Slika 16: Povečano izražanje PHLPP1/2 zmanjša izločanje inzulina, ki je stimuliran z glukozo. 
Langerhansovi otočki so bili transducirani z adenovirusi PHLPP 1 in PHLPP 2 ali LacZ. Izločanje inzulina je 
bilo izmerjeno eno uro po inkubaciji, s koncentracijo glukoze 2,8 mmol/L (beli stolpci, osnovna raven inzulina) 
in 16,7 mmol/L (sivi stolpci, stimulirana raven inzulina), in normaliziran na količino vsebovanega inzulina 
(A). Stimulacijski indeks inzulina kaže razmerje med stimulirano (16,7 mmol/L) in osnovno ravnjo (2,8 
mmol/L) izločanja inzulina (B). Predstavljen je rezultat iz ene serije človeških Langerhansovih otočkov. 
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5 DISCUSSION 
 
5.1 HIPPO PATHWAY 
 
Pancreas development is a complicated genetic programme, regulated by multiple 
transcription factors and regulatory signaling pathways, that allow the organ a correct cell 
and mass composition, in order to function properly (George et al., 2012). In recent years, 
Hippo pathway was demonstrated to regulate pancreas development as well as crucial 
cellular processes in -cell survival, and proliferation (Yuan et al., 2016; Riley et al., 2015; 
George et al., 2012). The loss of YAP expression in terminally differentiated mature 
endocrine cells namely -cells, correlated with a very low rate of  -cell proliferation and 
high sensitivity to apoptotic stimuli. This is critical for designing strategies for -cell-
targeted diabetic therapy, as diabetic -cells show higher apoptosis as well as impaired 
regenerative capacity. In mature pancreatic endocrine cells, YAP is eventually shut down 
and its expression limited to the exocrine acinar and duct cells. YAP expression disappears 
exactly at the point of islet development, when developmental endocrine transcription factor 
Neurogenine-3 (Ngn3) becomes present in order to perform endocrine cell differentiation, 
which reduces the ability of adult β-cells to re-enter the cell cycle and thus limit the 
proliferative potential of adult β-cells (George et al., 2015; Gao et al., 2014). 
 
Relevant to this context, our data showed that a constitutively active form of YAP 
(YAPS127A) effectively promotes human -cell proliferation and blocks -cell death under 
several diabetic conditions (inflammatory cytokines, glucotoxicity, lipotoxicity and 
oxidative stress). YAP is able to interact with many transcriptional factors and can therefore 
trigger a proliferative signaling in the cell. One of the most important transcription factors is 
FOXM1, which controls cell cycle proliferation, through regulation of G1/S, S as well as 
G2/M phase progression. Loss of FOXM1 impaired endogenous -cell proliferation and -
cell compensatory response under physiological and pathological conditions (Zhang et al., 
2006; Misfeldt et  al., 2008; Zhang et al., 2010), whereas its overexpression sufficiently 
induces -cell proliferation and restores the -cell mass (Davis et al., 2010). In human -
cells, the expression of this transcription factor is positively correlated with YAP expression, 
suggesting that YAP survival action is FOXM1 dependent (Yuan et al., 2016a). As loss of 
functional -cell mass is a critical common factor of both T1D and T2D, these findings 
suggest that YAP-induced -cell proliferation and survival would be an attractive 
therapeutic approach to repair dysfunctional -cells or restore declined functional -cell 
mass in diabetes.  
  
YAP overexpression strongly upregulates the small redox proteins thioredoxin 1 and 2 (Trx1 
and 2) in human islets and INS-1E cells. It was shown that YAP ability to block -cell 
apoptosis is dependent on antiapoptotic Trx1 and Trx2 (Yuan et al., 2016a). This redox-
Lupše B. Identification of signaling pathways controlling survival of pancreatic β-cells in diabetes.  
 M. SC. Thesis. Ljubljana, Univ. of Ljubljana, Biotechnical Faculty, Academic Study of Biotechnology, 2017 
46 
sensitive signaling operated by Trx1 and Trx2 is important in protecting the cells from 
oxidative stress and other ROS-dependent apoptotic stimuli such glucotoxicity and pro-
inflammatory cytokines. Such stress can namely destroy -cells, leading to development of 
T1D and T2D, if the Trx system would not properly cope against such oxidative assaults 
(Hotta et al., 1998; Yamamoto et al., 2008). Furthermore, Trx system is involved in the 
regulation and inhibition of stress-induced MST1 activity (Chae et al., 2012). As discussed 
before, MST1 is master regulator of -cell apoptosis under diabetic conditions and its 
aberrant activity impairs both -cell survival (through targeting intrinsic pathway of 
apoptosis) and function (through phosphorylation-dependent destruction of PDX1) 
(Ardestani et al., 2014). In -cells, Trx1/2 could be YAP-regulated intracellular signals to 
terminate MST1 hyper-activity and thus absence of YAP and subsequent impaired Trx 
response makes mature -cell highly sensitive to MST1-driven -cell apoptosis and loss of 
function.  
 
Additionally, in search for effective inhibition of MST1 activity in -cells, our working 
group discovered a novel MST1 inhibitor, neratinib (Ardestani et al., 2017b). My data 
showed that MST1 inhibition by neratinib has protective anti-apoptotic effects in -cells and 
human islets in vitro as well as diabetic rodent models in vivo. Neratinib effectively inhibited 
activation of pro-apoptotic kinase MST1 in various diabetic conditions (inflammatory 
cytokines, glucotoxicity, oxidative stress and lipotoxicity) and improved -cells survival. In 
T1D and T2D mouse models, neratinib showed ability to restore normoglycaemia in vivo. 
Neratinib is well tolerated in many subjects and show promising results for cancer therapy 
as currently tested in phase III of clinical trials for usage in breast cancer therapy (Chan et 
al., 2016). Based on our data, neratinib also showed promising results in β-cell-protective 
therapy of diabetes in preclinical mouse models. This is critically important since there are 
currently no therapies to halt -cell failure in diabetes and available therapies are directed in 
relieving symptoms of disease through stimulating insulin secretion from the remaining β-
cells in T2D, and through exogenous insulin therapy in T1D (Gao et al., 2016). 
 
Altogether, the above listed results support the importance of the Hippo pathway in the 
development of -cell failure in diabetes. Yet, more research is required towards better 
understanding the complexity and regulation of the entire Hippo signaling pathway in -cell 
physiology and pathogenesis. Misregulation in the Hippo pathway can reduce cell apoptosis 
and excessively initiates proliferative programs, with a high potential for uncontrolled 
expansion of multiple cell types and aberrant activation of oncogenic cell signaling. As YAP 
unusually increases cell proliferation, it is a potential oncoprotein, as it can enable possible 
cancer growth. Therefore, YAP levels should be always strictly regulated in order to limit 
YAP-mediated uncontrolled cell proliferation and -cell expansion. Blocking MST1 is a 
promising therapy, which may be used in the future. However, in T1D and T2D, where the 
usage of neratinib or any other MST1 inhibitors (Ardestani et al., 2017b) is chronic for a 
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longer period of time, more toxicological studies are necessary to test their safety and 
efficiency. 
 
5.2 MAMMALIAN TARGET OF RAPAMYCIN (mTOR) 
 
The mammalian target of rapamycin complex 1 (mTORC1) is the main metabolic molecule, 
attracting attention in pancreatic β-cell metabolism research. mTORC1 is especially well-
known for cellular growth and survival regulation, as it converts catabolic cellular 
metabolism to growth-promoting anabolic metabolism. While numerous findings 
demonstrated positive effects of mTORC1 regulation of β-cell survival, proliferation and 
function, under physiological responses to growth factors and nutrients (Kwon et al., 2004; 
Stamateris et al., 2016), more recent work showed that sustained mTORC1 hyper-activation 
triggered by chronic nutritional overload related to obesity and T2D leads to β-cells 
exhaustion and consequently β-cell dysfunction and death (Yuan et al., 2016b; Bartolomé et 
al., 2014). Such contradictory action of mTORC1 on β-cell function and viability is 
demonstrated in β-cell-specific TSC2-knock-out mice (Shigeyama et al., 2008; Blandino-
Rosano et al., 2012). In young mice, mTORC1 activation resulted in increased insulin 
secretion and islets mass and improved glucose homeostasis. In contrast, in old mice 
mTORC1 hyper-activation showed harmful impacts on β-cells survival, leading to oxidative 
stress, β-cell apoptosis and loss of β-cell mass. Therefore, increased β-cell mTORC1 activity 
is initially beneficial for glucose homeostasis, but its chronic activation with aging leads to 
diabetes development (Shigeyama et al., 2008; Blandino-Rosano et al., 2012; Yuan et al., 
2016b). 
 
Once mTORC1 is chronically hyper-activated, mTORC1-S6K1-mediated negative feedback 
loops cause long-term compensatory mechanisms resulting in inappropriately inhibition of 
insulin signaling and mTORC2-AKT pathway (Efeyan and Sabatini, 2010). This can explain 
the defective phosphorylation of AKT at Ser473 (site of mTORC2 phosphorylation) in 
stressed β-cells in T2D (Shao et al., 2000). Shut down of AKT's pro-survival signaling 
damages β-cell growth and proliferation and induces apoptosis, insulin resistance and 
eventually diabetes (Yuan et al., 2016b). Hyper-activated mTORC1 has at least four known 
negative loops including phosphorylation of IRS1/2, Grb10, and main mTORC2 
components, Sin1 and rictor (Briaud et al., 2005; Tremblay et al., 2007; Yu et al., 2011; 
Julien et al., 2010; Liu et al., 2013), and could potentially lead to impaired β-cell survival 
and function in diabetes. However, in physiological conditions, these loops balance 
intracellular mechanisms, for proper and controlled β-cell growth, survival and insulin 
signaling, whereas chronic and unbalanced activation of mTORC1 leads to loss of insulin 
and mTORC2 signaling (Fraenkel et al., 2008; Ardestani et al., 2017a).  
 
Our recently published data showed that the specific S6K1 inhibitor PF-4708671 is able to 
block mTORC1's main downstream protein S6K1, and thus increases insulin secretion in 
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human islets from individuals with T2D. We confirmed a profound decrease in 
phosphorylation of the S6K1’s crucial substrate, ribosomal protein S6, once the cells were 
treated with specific S6K1 inhibitor. Although rapamycin, a commonly used drug to inhibit 
mTORC1, is extensively used in diabetes studies, and can even restore insulin signaling and 
glucose homeostasis in the short term (Tremblay et al., 2007; Tzatsos and Kandror, 2006), 
the chronic exposure to rapamycin has opposite effects (Schreiber et al., 2015; Lamming et 
al., 2012; Houde et al., 2010). Such chronic exposure does not only block mTORC1, but 
also mTORC2, which is crucial for proper regulation of insulin signaling and β-cells mass 
(Shao et al., 2000). But, S6K1 inhibitor does not block pro-survival mTORC2-AKT 
signaling, as rapamycin exposure does. mTORC2 therefore stays activated, as presented in 
Fig. 10 and confirmed in our study (Yuan et al., 2016). Our data suggest that mTORC1 
hyperactivation may be one of the crucial signaling for diabetes development and can be 
exploited as a potential therapeutic target for T2D treatment. 
 
5.3 PH DOMAIN AND LEUCINE RICH REPEAT PROTEIN PHOSPHATASES 1 
AND 2 (PHLPP1/2) 
 
PHLPP phosphatases are key regulators of cell survival. Repression or aberrant 
hyperactivation of PHLPP can lead to several diseases, including cancer, cardiovascular 
disorders, insulin resistance and diabetes (Andreozzi et al., 2011; Liu et al., 2010). Andreozzi 
et al., (2011) showed that PHLPP is up-regulated in adipose and skeletal muscle tissues in 
obese patients and has negative effect on insulin action. Interestingly, Qiao et al. (2010) have 
demonstrated direct dephosphorylation of MST1 at inhibitory Thr387 site by PHLPP 
phosphatases, which promotes MST1 activation and induction of apoptosis.  Consistent with 
this finding and our search for molecules that activate MST1 under diabetic conditions, we 
found that PHLPPs are up-regulated in diabetic β-cells and could directly induce MST1 
activity (Ardestani et al., unpublished data). Conversely, Thr387 phosphorylation induced 
by AKT kinase results in MST1 inactivation and suppressed stress-induced apoptotic events 
(Jang et al., 2007). Thus, when dephosphorylated at Thr387, MST1 is capable to induce β-
cell death in pancreatic islets under diabetic setting. Such dephosphorylation is induced by 
PHLPPs. My data show upregulation of both PHLPP 1 and 2 isoforms, in isolated islets of 
different diabetic mouse models; from db/db and HFD obese diabetic mice, together with 
mTORC1 as well as MST1 activation.  
Since mTORC1 is hyperactivated in diabetic mice and thus indirectly controls AKT by 
negative feedback loops, we also believe that PHLPP phosphatases may dephosphorylate 
AKT at Ser473 (mTORC2 phosphorylation site) in vivo, and thus additionally block AKT's 
pro-survival effects in diabetic β-cells in mice as well as in humans. Gao et al. (2005) first 
showed that PHLPP is able to interact with AKT and dephosphorylates it at Ser473, leading 
to cell apoptosis. After that, multiple studies have confimed this original observation, 
suggesting the importance of PHLPP-AKT interaction in insulin resistance and diabetes, 
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where silencing of PHLPPs can restore insulin signaling (Xing et al., 2016; Caricilli et al., 
2012). Further, expression of PHLPP is regulated by mTOR (Xing et al., 2016; Liu et al., 
2010). Liu et al. (2010) showed that rapamycin treatment or mTOR knockdown block 
mTOR activity and consequently decrease PHLPP expression, while the rapamycin-
insensitive p70S6K mutant shows increased expression of PHLPP. Additionally, Liu et al. 
(2011) provided some evidence that PHLPP can also control mTORC1's main downstream 
protein S6K1 by dephosphorylating it at Thr389. Dephosphorylation was induced by amino 
acid starvation and was markedly decreased in MEF cells isolated from PHLPP1 knock-out 
mice. Consistently, my study showed that treatment of MEF TSC2 knock-out cells, where 
mTORC1 is hyperactivated, with rapamycin markedly reduced PHLPPs protein expression. 
In line with this data, pharmacological activation of mTORC1 using the small molecule 3-
BDO up-regulates PHLPPs proteins. Same result was achieved by targeting the main 
component of the mTORC1, Raptor, by siRNA silencing in human islets isolated from T2D 
patients, suggesting that mTORC1-dependent PHLPP regulation can have disease-related 
implication in the β-cell driven pathogenesis in T2D. Namely, adenoviral overexpression of 
PHLPP in human islets results in impaired glucose-stimulated insulin secretion suggesting 
PHLPPs action on insulin secretion. The loss of PHLPP signaling was already reported in 
some types of cancers, implying that such increased levels of PHLPPs may potentially help 
in cancer therapy (Liu et al., 2009). Nevertheless, PHLPP signaling might be a key 
determinant factor for the pathogenesis of insulin resistance and its inhibition by selective 
PHLPP inhibitors (Sierecki et al., 2010) could be potentially useful in diabetes and obesity.   
 
Taken together, our observations demonstrate an important role of PHLPP in regulating pro-
survival AKT and pro-apoptotic MST1. Under physiological conditions, this signaling 
triangle in which low PHLPPs levels can simultaneously activate and inactivate AKT and 
MST1 (two PHLPP substrates) ensuring a balance for β-cell survival and apoptosis. In 
diabetic conditions, PHLLPs up-regulation triggers higher activation of MST1 and 
inactivation of AKT, leading to β-cell death and dysfunction. 
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6 CONCLUSIONS 
 
In the experimental part of my master thesis, I demonstrated that: 
 
1) Neratinib as novel inhibitor of Hippo kinase MST1 blocked MST1 activation and 
protected β-cells and primary human islets under diabetogenic conditions. 
 
2) Overexpression of the Hippo transcriptional co-activator YAP suppressed apoptosis 
triggered by a complex diabetic milieu in β-cells and isolated human islets. 
 
3) mTORC1 activity was highly increased in mouse and human T2D diabetic islets. 
Inhibition of mTORC1 markedly restored mTORC2 signaling and insulin secretion 
in human T2D islets and HFD mouse islets. 
 
4) PHLPP1 and PHLPP2 are up-regulated in mouse T2D diabetic islets and their 
levels are regulated by mTORC1 signaling under diabetic conditions. PHLPPs 
overexpression impaired insulin secretion in human islets. 
 
  
Lupše B. Identification of signaling pathways controlling survival of pancreatic β-cells in diabetes.  
 M. SC. Thesis. Ljubljana, Univ. of Ljubljana, Biotechnical Faculty, Academic Study of Biotechnology, 2017 
51 
7 SUMMARY (POVZETEK) 
 
7.1 SUMMARY 
 
The pancreas is an organ responsible for regulation of glucose homeostasis. Specifically, the 
endocrine pancreas so-called islets of Langerhans are embedded in the exocrine tissue, and 
coordinate glucose and metabolic homeostasis. The most abundant cells in the islets are β-
cells, which secrete insulin, the hormone for glucose uptake. Any dysregulation in the islets’ 
endocrine function leads to hypo- or hyperglycaemia. Chronic hyperglycaemia became a 
serious health problem particularly in developing countries, resulting in severe metabolic 
diseases, such as type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D). In T1D 
is the loss of β‐cell mass associated with immune mediated destruction, whereas is T2D 
initially triggered by insulin resistance and in later stages by programmed cell death or 
apoptosis of pancreatic β‐cells. 
 
Hippo is the key intracellular pathway, responsible for cell proliferation, apoptosis and 
differentiation. Several lines of evidence describe the importance of Hippo pathway 
components such as mammalian Sterile-20-like kinases 1 (MST1) and YAP transcriptional 
co-activator in regulation of β-cell survival and proliferation. Since YAP is not expressed in 
mature β-cells, this could be the reason for the extremely low rate of β-cell proliferation and 
high susceptibility to apoptotic stimuli. Our working group re-expressed the constitutively 
active form of YAP (YAPS127A) in β-cells and observed higher β-cell proliferation and 
protection from apoptosis. Additionally, our working group has identified a novel small 
molecule inhibitor of MST1, a master inducer of β-cell apoptosis, to be tested for its efficacy 
in β-cell protection in diabetes. Inhibition of MST1 by neratinib remarkably improved β-cell 
survival in a β-cell line and in human islets in vitro. 
 
Mammalian target of rapamycin (mTOR) is a regulator of cell proliferation and cell growth, 
which forms two structually distinct complexes; mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). Since both complexes are crucial for cell survival, they need to be 
strictly regulated. mTORC1 is the master regulator of anabolic growth and promotes β-cell 
growth and survival, whereas its hyper-activation could induce β-cell failure in diabetes. 
Especially diabetic T2D islets showed elevated mTORC1 activation, together with increased 
expression of pro-apoptotic proteins. mTORC1 hyper-activation further diminished 
mTORC2-AKT signaling, due to the mTORC1-mediated negative feedback loops.  
mTORC1 inhibition using a S6K1 selective inhibitor or knockdown of Raptor (main 
mTORC1 component) decreased mTORC1 activity in diabetic conditions, restored 
mTORC2 activity and improved β-cell function. This suggests mTORC1 hyper-activation 
as the important pathogenic stimuli, contributing to impaired function and survival of β-cells 
in T2D. 
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PHLPP1/2 (Ph domain and leucine rich repeat protein phosphatases 1 and 2) are important 
phosphatases that regulate apoptosis by targeted dephosphorylation of their substrates such 
as MST1 and AKT. PHLPPs are induced and correlated with activation of mTORC1 and 
MST1 under diabetic conditions in isolated islets from T2D diabetic mice. Also, mTORC1 
was shown as strong regulator of PHLPPs up-regulation and MST1 activation in diabetic β-
cell and T2D islets. Additionally, PHLPPs overexpression induces impaired insulin 
secretion in non-diabetic isolated human islets. These findings suggest that PHLPPs as 
potential key proteins for the initiation of the apoptotic pathway in diabetic β-cells. 
 
7.2 POVZETEK  
 
Trebušna slinavka je glavna žleza, ki uravnava homeostazo glukoze. Je v zgornjem delu 
trebuha, kjer je obdana s tankim črevesjem, želodcem, vranico in jetri, in je strukturno 
razdeljena v vrat, telo in rep. Funkcionalno ima trebušna slinavka endokrini in eksokrini del. 
Eksokrini ima vlogo tvorbe prebavnih encimov, endokrini pa izloča hormone, ki uravnavajo 
koncentracijo glukoze v krvi in njen privzem v celice. Natančneje, Langerhansovi otočki 
predstavljajo endokrini del, ki je obdan z eksokrinim tkivom, in so sestavljeni iz več različnih 
celic. Najbolj zastopane celice v otočkih so β-celice, ki izločajo inzulin za regulacijo 
glukoze, kar lahko ob napačnem signaliziranju vodi do hipo- ali hiper-glikemije. Druge 
celicev Langerhansovih otočkih so: α-celice, δ-celice, ε-celice in celice PP. 
Kronična hiperglikemija ali kronično povišanje sladkorja v krvi je postal hud zdravstveni 
problem v mnogih državah, še posebej v državah v razvoju, saj povzroča številne zaplete 
povezane s srčno-žilnimi obolenji, obolenji oči, ledvic in živčnega sistema. Hiperglikemija 
se lahko razvije pri sladkorni bolezni tipa 1 (SBT1) ali tipa 2 (SBT2). SBT1 se pojavlja zlasti 
pri mlajših osebah in je praviloma pogojena z avtoimunostjo, kar vodi do imunskega napada 
na lastne β-celice trebušne slinavke. SBT2 pa se pojavi predvsem v povezavi z debelostjo v 
kasnejših obdobjih življenja, in je z 90 % prevladujoča oblika sladkorne bolezni. Glavni 
dejavnik tveganja za nastanek sladkorne bolezni je prekomerna telesna teža in telesna 
neaktivnost. Oba tipa sladkorne bolezni sta povezana s propadanjem in izgubo β-celične 
mase, bodosi zaradi avtoimunskega procesa ali na račun patološko povišane aktivacije 
apoptoze. β-celice to izgubo sprva nadomestijo s povečanim izločanjem inzulina iz 
preostalih celic. Aktivacija omenjene apoptotične poti poteka preko aktivacije pro-
apoptotičnih proteinov, kot so proteini iz družine kaspaz in mammalian Sterile-20-like 
kinaza 1 (MST1). Apoptoza je sprožena preko intrinzične poti z mitohodrijem, ali pa preko 
ekstrinzične poti z direktno aktivacijo kaspaz, brez neposrednega vpliva mitohondrija. 
 
Hippo signalna pot je ena glavnih mehanizmov v celici, odgovorna za rast in diferenciacijo 
organov, kot tudi za aktivacijo apoptoze. Njeno delovanje regulirajo mammalian Sterile-20-
like kinaze 1 in 2 (MST1/2), large tumor suppressor 1 in 2 (LATS1/2) in YAP/TAZ 
transkripcijski ko-aktivator. Ob aktivaciji Hippo signalne poti MST1/2 fosforilira in aktivira 
LSTS1/2, ta pa nato s fosforilacijo inaktivira YAP/TAZ transkripcijski ko-aktivator. 
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Fosforiliran YAP/TAZ tako ni sposoben translokacije v jedro, kjer bi sicer sprožil 
prepisovanje genov, ampak se s pomočjo proteosoma razgradi v citoplazmi. Neaktivna 
Hippo signalna pot z neaktiviranim MST1/2 ni sposobna aktivirati LATS1/2, s čimer 
YAP/TAZ ostane nefosforiliran. Slednji preide v jedro, kjer s pomočjo TEA domain (TEAD) 
družine transkripcijskih faktorjev, in tudi drugih, vodi do začetka prepisovanja genov 
udeleženih v rasti in proliferaciji celice. Hippo signalna pot je tako izrednega pomena za 
regulacijo rasti in preživetja celice in tako ključna pri propadanju β-celic in njihovi 
zmanjšani funkciji. 
 
YAP transkripcijski co-faktor se ne izraža v zrelih β-celicah, kar vodi v njihovo zmanjšano 
proliferacijo. Na račun tega je naša raziskovalna skupina sklepala, da bi izražanje YAP-a v 
zrelih β-celicah trebušne slinavke lahko ponovno spodbudilo njihovo rast in proliferacijo. 
Preko adenovirusnega vektorja smo tako izrazili konstitutivno obliko YAP transkripcijskega 
co-faktorja (YAPS127A) v insulinoma podganji celični liniji INS-1E in zrelih diabetičnih β-
celicah človeške trebušne slinavke. Ser127 je bil zamenjan z aminokilsino alanin in zato 
neobčutljiv na LATS1/2 fosforilacijo in posledično inaktivacijo. Opazili smo močno 
povišano proliferacijo in zmanjšano apoptozo celic. Poleg povečanega YAP izražanja se je 
namreč povečalo tudi izražanje transkripcijskega faktorja forehead box M1 (FOXM1) in 
majhnih redoks proteinov tioredoksin 1 in 2 (Trx1 / 2). Bolj podrobno, FOXM1 je eden 
pomembnejših faktorjev za celično delitev in proliferacijo, saj preko G1/S, S, G2/M faz 
regulira celični cikel, Trx1/2 pa sta proteina, ki ščitita proti oksidativnemu stresu, ki je glavni 
povzročitelj smrti β-celic. Z omenjenim poskusom smo dokazali, da lahko ponovno izražen 
YAP, preko regulacije FOXM1 transkripcijskega faktorja in Trx1/2 proteinov, uspešno 
zmanjša propadanje β-celic.   
 
Z naslednjim poskusom se je naša raziskovalna skupina usmerila na iskanje inhibitorja, ki 
bi uspešno zavrl apoptotično delovanje Hippo signalne poti v β-celicah.Osredotočili smo se 
na iskanje inhibitorja, ki bi blokiral aktivnost MST1 kinaze. MST1 je aktiviran z interakcijo 
več proteinov (NF2, PHLPP1/2), ki ga fosforilirajo ali defosforilirajo, fragmentacija s 
pomočjo kaspaz pa vodi do njegove popolne aktivacije. MST1 je namreč ključen pri 
apoptozi diabetičnih β-celic, kjer je izražanje tovrstne kinaze še posebej povišano. 
Fosforiliran in aktiviran MST1 lahko preko aktivacije LATS1/2 kinaz sproži apoptozo, kot 
tudi z regulacijo FOXO transkripcijskih faktorjev in H2B histonov v jedru. Hkrati MST1 v 
β-celicah s fosforilacijo blokira transkripcijski faktor PDX1, ki je bistven za produkcijo 
inzulina in rast β-celic. Odkrili smo, da MST1 inhibitor neratinib znatno blokira njegovo 
delovanje in poveča preživetje diabetičnih β-celic. V celicah zdravljenimi z neratinibom smo 
zaznali povišano izražanje PDX1 transkripcijskega faktorja, ključnega za normalno funkcijo 
celic, in drastično zmanjšano izražanje pro-apoptotičnih proteinov kot sta MST1 in kaspaza 
3. Neratinib je hkrati v SBT2 in SBT1 miškah in vivo uspešno normaliziral povečano 
koncentracijo glukoze v krvi. Z omenjenima poskusoma smo pokazali, da lahko pravilna 
regulacija Hippo signalne poti uspešno reši povečano β-celično smrt v diabetični trebušni 
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slinavki, in je posledično potencialni kandidat za zdravljenje sladkorne bolezni. Kljub temu 
pa ne smemo spregledati dejstva, da lahko z manipulacijo Hippo signalne poti povišamo 
proliferativen učinek β-celic, kar lahko posledično vodi do nastanka tumorjev.  
  
Mammalian target of rapamycin (mTOR) je regulator celične proliferacije in rasti, ki tvori 
dva strukturno ločena kompleksa; mTOR kompleks 1 (mTORC1) in mTOR kompleks 2 
(mTORC2). Oba kompleksa sestojita iz mTOR kinaze in njunih partnerskih proteinov in sta 
ključna za preživetje celic, zato mora celica njuno izražanje strogo regulirati. mTORC1 je v 
celici aktiviran preko rastnih faktorjev (inzulin ali IGF) in celičnih nutrientov (amino kisline 
in glukoze), za razliko od mTORC2, ki je aktiviran le s strani rastnih faktorjev. mTORC2 v 
β-celici vzdržuje normalno rast in skrbi za njihovo preživetje. mTORC2 je pomemben 
aktivator AKT kinaze, ki dalje aktivira mTORC1. Ta kompleks regulira anabolično rast in 
sintezo proteinov, preko ribosomalne S6 kinaze 1 (S6K1) in initiation factor 4E binding 
protein 1 (4E-BP1). Ko je v celici na voljo dovolj hranil, aktiviran mTORC1 fosforilira in 
aktivira S6K1, ki naprej regulira S6 protein ribosomalne podenote. Nefosforiliran 4E-BP1 
služi kot supresor translacijskega mehanizma. Ko pa je 4E-BP1fosforiliran in aktiviran se 
le-ta odstrani iz translacijskega mehanizma in skupaj s S6K1 omogoči začetek sinteze 
proteinov in rast celic. Za pravilno delovanje mTORC1 je ključna tudi pravilna negativna 
regulacija, saj lahko povečana aktivacija vodi v nenadzorovano rast celic. Negativna 
regulacija je sprožena preko S6K1 negativnih povratnih zank, ki lahko inaktivirajo mTORC2 
in substrat inzulinskega receptorja 1 (IRS-1), in na ta način onemogočijo signalno pot, 
sproženo preko rastnih faktorjev. Ko je ta pot inhibirana, tuberous sclerosis kompleks 1 in 2 
(TSC1/2), AMP-aktivirana proteinska kinaza (AMPK) in PRAS40 negativno regulirajo in 
inaktivirajo mTORC1 in tako ponovno vzpostavijo normalno delovanje celice.  
 
Naša nedavna študija je pokazala, da je mTORC1 patološko nekontrolirano aktiviran v 
diabetičnih β-celicah. Njegova povišana aktivacija povzroči apoptozo in zmanjša preživetje 
SBT2 β-celic človeške trebušne slinavke. Na račun povišane aktivacije mTORC1 preko 
S6K1 in S6 proteina, smo zaznali zmanjšano izražanje mTORC2 preko AKT kinaze in N-
myc downstream regulated 1 (NDRG1), kar nakazuje na oslabljeno delovanje mTORC2 v 
diabetičnih β-celicah, na račun negativnih povratnih zank iz mTORC1. Našteto vodi v 
zmanjšano funkcijo β-celic in posledično pospešeno propadanje celic. V primeru akutnega 
zdravljenja β-celic z rapamicinom, ki je inhibitor mTORC1, se aktiviranost mTORC1 
zmanjša, kronična uporaba pa pripelje tudi do inhibicije mTORC2, ki pa je nujno potreben 
za normalno delovanje β-celic. Naša skupina je v iskanju specifičnega inhibitorja mTORC1 
našla inhibitor PF-4708671, ki je visoko selektiven za S6K1 in privede do inaktivacije 
negativnih povratnih zank speljanih preko aktiviranega S6K1. Poleg tega ta inhibitor ni 
specifičen za mTORC2 in ta posledično ostane aktiviran. Na račun inaktiviranosti mTORC1-
S6K1 signalne poti v diabetičnih razmerah, se aktivnost mTORC2 izboljša, kar hkrati 
izboljša β-celično funkcijo in preživetje. Hiperaktivacija mTORC1 tako nakazuje 
pomemben patogeni dražljaj, ki prispeva k nastanku sladkorne bolezni. 
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V hipotalamusu podgan nedavno odkrito družino fosfataz PHLPP (PH domain and Leucine 
rich repeat Protein Phosphatases) sestavljata PHLPP1 in PHLPP2. PHLPP1 je, za razliko od 
PHLPP2, stukturno sestavljen iz α in β izoforme, z daljšim zaporedjem amino kislin. Obe 
fosfatazi za svoje delovanje potrebujeta dvovalentni kation, kot sta magnezij in mangan. Šele 
v zadnjem desetletju so proteina začeli preučevati bolj podrobno in ugotovili, da regulira 
pomembne signalne poti, ki so bistvene za normalno delovanje celic. Prvič je bil PHLPP 
namreč opisan kot negativen regulator kinaze AKT, ki signalizira preživetje celic. Veliko 
raziskav je sledilo, ki so opisovale vpletenost PHLPP1/2 fosfataz v regulacijo signalnih poti 
v različnih obolenjih kot sta rak in sladkorna bolezen. Sčasoma je prišlo do odkritja novih 
proteinov, ki lahko interegirajo s PHLPP1/2, med katerimi so najpomembnejši PKC 
(proteinska kinaza C), S6K1, Raf1 in MST1. Proteini, ki jih regulira PHLPP1/2, so znani 
tudi po svoji proliferativni sposobnosti, kar lahko ob nenadzorovanem in povečanem 
izražanju pomeni tvorbo in nastanek tumorjev. PHLPP1/2 je zaradi tega pomemben supresor 
tvorbe rakavih celic.  
 
Pri preučevanju β-celic smo se osredotočili predvsem na kinazi AKT in MST1, ki regulirata 
preživetje β-celic, in sta regulirani preko fosfataz PHLPP1/2. Kot že omenjeno je aktiviran 
AKT pomemben protein z anti-apoptotičnim učinkom, ki skrbi za rast in proliferacijo β-
celic. V nasprotju je MST1 pro-apoptotični protein, ki ima pomembno vlogo pri aktivaciji 
Hippo signalne poti in ob aktivaciji zmanjša β-celično funkcijo in njeno preživetje. Kot že 
omenjeno je MST1 dobro znana molekula, ki fosforilira LATS1/2 kinaze in posledično vodi 
v degradacijo YAP transkripcijskega ko-aktivatorja. Slednji zato ni sposoben reagirati s 
transkripcijskimi faktorji in sprožiti prepisovanje genov, zaradi česar β-celice propadejo. 
Pokazali smo, da so diabetični SBT2 mišji modeli, kot tudi miši hranjene s hrano z visoko 
vsebnostjo maščob (HFD), imele izredno povečano izražanje PHLPP1/2. Hkrati je bilo 
preko proteinov S6K1 in S6 moč opaziti povišano izražanje mTORC1, kar sovpada z 
dokazano hiperaktivacijo mTORC1 v diabetičnih β-celicah. Povečano je bilo tudi izražanje 
pro-apoptotičnega MST1 proteina. Povezanost med hiperaktivacijo mTORC1 in posledično 
povišanim izražanjem PHLPP1/2, je moja raziskovalna skupina želela potrditi z uporabo 
podganje inzulinoma celične linije INS-1E in človeških β-celic. mTORC1 smo pri obeh 
aktivirali z aktivatorjem 3-BDO in opazili enak vzorec izražanja proteinov. Namreč, poleg 
proteinov S6K1 in S6, ki sicer predstavljata izražanje mTORC1, smo opazili še povišano 
izražanje pro-apoptotičnega MST1. Prikazali smo tudi inhibicijo mTOR kompleksa 1 preko 
rapamicina in specifičnega utišanja njegovega partnerskega proteina raptor, ter s tem dosegli 
utišanje mTORC1 in posledično zmanjšano izražanje PHLPP fosfataz. S tem smo prikazali 
veliko povezanost med mTORC1 in PHLPP1/2, kjer mTORC1 regulira izražanje 
PHLPP1/2, in obratno, pri sladkorni bolezni. Kot že poznano sta fosfatazi PHLPP1/2 močno 
povezani z defosforilacijo in aktivacijo MST1, kar je po našem mnenju eden glavnih 
mehanizmov za povečano propadanje diabetičnih β-celic tako in vitro kot in vivo. PHLPP1/2 
je namreč zmožen defosforilirati MST1 na Thr387, kar povzroči njegovo aktivacijo in 
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začetek apoptoze. Omenjeno defosforilacijo smo potrdili v β-celicah človeške trebušne 
slinavke, na račun  adenovirusne povečane ekspresije PHLPP1/2. Obe fosfatazi regulirata 
tudi izražanje proteina AKT, z defosforilacijo Ser473. Slednja pomeni njegovo inaktivacijo 
in dodatno inhibicijo signalnih poti, ki so odgovorne za preživetje β-celic. V SBT2 človeških 
β-celicah in INS-1E celicah smo testirali inhibitorja PHLPP1/2 fosfataz, in pokazali 
zmanjšano izražanje MST1 ter povečano izražanje AKT. Opisano še dodatno potrjuje 
pomembno vlogo PHLPP1/2 fosfataz pri propadanju diabetične β-celične mase. Zaradi 
nedavnega odkritja PHLPP1/2 fosfataz, je potrebnih še veliko podrobnih preiskav o njuni 
vlogi v celici. Lahko bi se izkazale kot pomembne tarče zdravljenja tako sladkorne bolezni 
kot rakavih obolenj.  
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